data_1fgd_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1fgd _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . 0.463 ' HB3' ' CB ' ' A' ' 413' ' ' TYR . 15.3 m . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -77.77 -172.9 1.61 Allowed 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.956 2.437 . . . . 0.0 112.731 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.26 134.23 23.02 Favored 'General case' 0 N--CA 1.518 2.961 0 CA-C-O 121.031 0.443 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.38 -43.87 2.05 Favored Glycine 0 N--CA 1.509 3.517 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . 0.463 ' CB ' ' HB3' ' A' ' 409' ' ' CYS . 51.3 m-85 -84.89 87.44 7.34 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.81 -176.32 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.14 0 O-C-N 121.582 -0.699 . . . . 0.0 111.715 -177.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.563 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.1 mm? -103.1 116.87 33.34 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.5 -172.17 2.5 Favored 'General case' 0 N--CA 1.512 2.636 0 O-C-N 122.097 -0.377 . . . . 0.0 110.766 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 56.8 -87.25 0.02 OUTLIER 'General case' 0 N--CA 1.513 2.701 0 C-N-CA 123.233 0.613 . . . . 0.0 110.289 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -133.38 44.58 1.18 Allowed Glycine 0 N--CA 1.502 3.078 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 178.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . 0.563 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 18.6 t80 70.51 64.97 0.2 Allowed 'General case' 0 N--CA 1.505 2.315 0 CA-C-O 121.992 0.901 . . . . 0.0 109.491 -179.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.2 pp -135.28 152.53 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.713 0 O-C-N 121.865 -0.522 . . . . 0.0 109.858 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.1 m -62.02 109.2 1.21 Allowed 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 121.242 0.544 . . . . 0.0 110.108 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.4 m -91.0 149.27 21.91 Favored 'General case' 0 N--CA 1.512 2.651 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.342 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -74.67 -173.35 1.79 Allowed 'General case' 0 N--CA 1.503 2.221 0 CA-C-O 121.231 0.538 . . . . 0.0 110.992 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . 0.654 HG12 ' OXT' ' A' ' 426' ' ' GLU . 11.8 tt -174.78 -50.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.886 0 O-C-N 121.884 -0.51 . . . . 0.0 110.99 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 61.93 58.26 1.95 Allowed 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . 0.654 ' OXT' HG12 ' A' ' 424' ' ' ILE . 1.1 mp0 . . . . . 0 N--CA 1.521 3.081 0 C-N-CA 123.962 0.905 . . . . 0.0 110.658 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.556 1.189 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.53 179.05 6.8 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.857 2.371 . . . . 0.0 112.866 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -46.73 133.91 10.21 Favored 'General case' 0 N--CA 1.521 3.083 0 CA-C-O 121.106 0.479 . . . . 0.0 111.271 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 95.38 -49.28 1.89 Allowed Glycine 0 N--CA 1.507 3.397 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 -177.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -81.14 88.42 6.0 Favored 'General case' 0 N--CA 1.499 2.006 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 178.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . 0.439 HD12 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -95.39 -176.35 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.28 0 O-C-N 121.522 -0.737 . . . . 0.0 110.417 -178.857 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.2 OUTLIER -104.98 139.01 40.31 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.591 -0.693 . . . . 0.0 109.414 179.704 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.51 -173.54 2.5 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -54.07 119.25 4.82 Favored 'General case' 0 N--CA 1.515 2.799 0 CA-C-O 121.113 0.482 . . . . 0.0 110.399 -179.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.13 -4.44 31.7 Favored Glycine 0 N--CA 1.506 3.34 0 CA-C-O 118.775 -1.014 . . . . 0.0 111.862 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 22.7 t80 68.15 66.86 0.34 Allowed 'General case' 0 N--CA 1.508 2.428 0 CA-C-N 119.505 1.652 . . . . 0.0 109.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 415' ' ' LEU . 2.1 pp -135.79 152.83 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.575 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.7 t -70.93 115.75 10.43 Favored 'General case' 0 N--CA 1.511 2.614 0 CA-C-O 121.398 0.618 . . . . 0.0 111.764 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 422' ' ' THR . . . . . 0.439 ' HB ' HD12 ' A' ' 414' ' ' ILE . 1.7 m -96.63 162.9 13.25 Favored 'General case' 0 N--CA 1.513 2.685 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -63.32 -173.8 0.07 Allowed 'General case' 0 N--CA 1.504 2.264 0 CA-C-O 121.644 0.735 . . . . 0.0 110.971 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -79.63 -34.63 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 121.509 -0.744 . . . . 0.0 109.876 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 57.71 52.32 8.34 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-O 121.771 0.796 . . . . 0.0 110.168 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.507 2.386 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.878 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 CA--C 1.556 1.2 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -75.68 -168.97 0.59 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.982 2.455 . . . . 0.0 112.477 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -47.11 130.4 12.59 Favored 'General case' 0 N--CA 1.519 2.99 0 CA-C-O 121.031 0.443 . . . . 0.0 111.183 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.71 -49.05 1.46 Allowed Glycine 0 N--CA 1.508 3.475 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -80.7 88.57 5.76 Favored 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -86.95 -172.97 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.338 0 CA-C-O 121.352 0.596 . . . . 0.0 112.474 -176.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.431 HD21 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -104.44 153.96 20.46 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.853 -0.53 . . . . 0.0 109.925 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . 0.433 ' HB2' ' OG1' ' A' ' 422' ' ' THR . 0.4 OUTLIER -106.25 -171.54 1.92 Allowed 'General case' 0 N--CA 1.514 2.766 0 O-C-N 121.937 -0.477 . . . . 0.0 111.003 179.623 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -51.29 130.17 26.24 Favored 'General case' 0 N--CA 1.515 2.789 0 CA-C-O 121.16 0.505 . . . . 0.0 110.855 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 96.81 -6.12 64.43 Favored Glycine 0 N--CA 1.507 3.409 0 CA-C-O 119.036 -0.869 . . . . 0.0 111.453 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 25.9 t80 68.43 71.41 0.3 Allowed 'General case' 0 N--CA 1.509 2.479 0 CA-C-N 119.092 1.446 . . . . 0.0 109.229 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.6 153.94 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.497 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.718 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . 0.431 ' HA ' HD21 ' A' ' 415' ' ' LEU . 0.1 OUTLIER -60.0 124.98 21.9 Favored 'General case' 0 N--CA 1.516 2.848 0 CA-C-O 121.013 0.435 . . . . 0.0 111.382 -178.623 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 422' ' ' THR . . . . . 0.433 ' OG1' ' HB2' ' A' ' 416' ' ' ASP . 6.5 m -134.3 150.03 50.94 Favored 'General case' 0 N--CA 1.509 2.506 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -91.82 143.61 26.34 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 122.405 1.098 . . . . 0.0 111.04 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 20.9 tt -55.04 -37.06 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.921 178.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 55.25 53.43 10.05 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-O 121.692 0.758 . . . . 0.0 110.416 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.478 0 O-C-N 121.931 -0.481 . . . . 0.0 110.045 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 1.2 m . . . . . 0 CA--C 1.558 1.288 0 N-CA-C 110.61 -0.144 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -76.17 177.84 8.25 Favored 'Trans proline' 0 N--CA 1.496 1.676 0 C-N-CA 123.007 2.471 . . . . 0.0 113.282 -178.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.82 134.02 25.75 Favored 'General case' 0 N--CA 1.518 2.959 0 CA-C-O 121.032 0.444 . . . . 0.0 111.194 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.49 -43.81 2.31 Favored Glycine 0 N--CA 1.508 3.484 0 N-CA-C 108.761 -1.735 . . . . 0.0 108.761 -177.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . 0.488 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 74.6 m-85 -85.74 75.77 10.03 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 2.1 pt -67.08 172.69 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.527 3.413 0 O-C-N 121.568 -0.708 . . . . 0.0 112.32 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -105.48 119.74 39.87 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . 0.4 ' CB ' HD13 ' A' ' 420' ' ' ILE . 0.1 OUTLIER -82.98 -170.56 3.09 Favored 'General case' 0 N--CA 1.514 2.77 0 O-C-N 122.004 -0.435 . . . . 0.0 111.416 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -49.44 123.01 6.86 Favored 'General case' 0 N--CA 1.516 2.839 0 CA-C-O 121.202 0.525 . . . . 0.0 110.866 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 95.03 -0.24 64.16 Favored Glycine 0 N--CA 1.507 3.382 0 CA-C-O 118.909 -0.939 . . . . 0.0 111.794 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 20.6 t80 66.44 71.44 0.4 Allowed 'General case' 0 N--CA 1.506 2.352 0 CA-C-N 119.306 1.553 . . . . 0.0 109.34 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . 0.4 HD13 ' CB ' ' A' ' 416' ' ' ASP . 2.1 pp -133.15 151.0 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.479 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.3 m -63.74 104.1 0.63 Allowed 'General case' 0 N--CA 1.511 2.607 0 CA-C-O 121.532 0.682 . . . . 0.0 112.681 -176.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 3.5 m -89.19 155.41 19.43 Favored 'General case' 0 N--CA 1.516 2.861 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.57 -171.57 0.28 Allowed 'General case' 0 N--CA 1.506 2.347 0 CA-C-O 121.455 0.645 . . . . 0.0 111.457 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 3.6 tt -115.84 -139.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.283 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 64.16 83.0 0.17 Allowed 'General case' 0 N--CA 1.512 2.649 0 CA-C-N 120.064 1.302 . . . . 0.0 110.131 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.522 3.143 0 C-N-CA 123.722 0.809 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 22.3 m . . . . . 0 CA--C 1.556 1.199 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.92 -174.57 2.23 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 122.866 2.378 . . . . 0.0 112.764 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.99 132.44 9.34 Favored 'General case' 0 N--CA 1.52 3.052 0 C-N-CA 122.756 0.422 . . . . 0.0 111.492 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -49.59 2.13 Favored Glycine 0 N--CA 1.505 3.236 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -178.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 37.4 m-85 -77.41 85.68 3.81 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.27 -172.86 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.521 3.081 0 O-C-N 121.778 -0.576 . . . . 0.0 110.805 -178.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.9 OUTLIER -104.13 121.18 42.7 Favored 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.28 -174.41 5.21 Favored 'General case' 0 N--CA 1.512 2.657 0 O-C-N 121.956 -0.465 . . . . 0.0 111.1 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -54.01 116.43 2.56 Favored 'General case' 0 N--CA 1.513 2.717 0 CA-C-O 121.215 0.531 . . . . 0.0 110.124 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.57 -3.93 30.92 Favored Glycine 0 N--CA 1.507 3.368 0 CA-C-O 118.773 -1.015 . . . . 0.0 111.776 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 21.0 t80 68.26 69.21 0.32 Allowed 'General case' 0 N--CA 1.505 2.286 0 CA-C-N 119.49 1.645 . . . . 0.0 109.916 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 415' ' ' LEU . 2.1 pp -139.09 151.99 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.501 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.8 t -71.11 114.17 8.9 Favored 'General case' 0 N--CA 1.512 2.652 0 O-C-N 121.613 -0.679 . . . . 0.0 110.689 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.17 -173.92 3.07 Favored 'General case' 0 N--CA 1.516 2.863 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.24 -172.2 0.87 Allowed 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.623 -0.673 . . . . 0.0 111.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . 0.418 HG12 ' HB2' ' A' ' 426' ' ' GLU . 0.4 OUTLIER -84.91 -41.25 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.766 -0.583 . . . . 0.0 110.015 -179.903 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 53.59 47.19 24.46 Favored 'General case' 0 N--CA 1.511 2.623 0 CA-C-O 121.531 0.681 . . . . 0.0 111.027 178.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . 0.418 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.871 -0.518 . . . . 0.0 110.113 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 CA--C 1.557 1.232 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -76.92 -170.7 0.96 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 123.009 2.472 . . . . 0.0 112.605 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -47.2 130.21 12.8 Favored 'General case' 0 N--CA 1.521 3.086 0 CA-C-O 120.878 0.37 . . . . 0.0 111.063 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . 0.451 ' HA3' HG13 ' A' ' 424' ' ' ILE . . . 95.27 -48.73 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -78.71 86.65 4.65 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 8.4 pt -89.7 -170.93 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.166 0 O-C-N 121.565 -0.71 . . . . 0.0 111.523 -178.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.484 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -111.86 120.57 42.41 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.45 -173.94 2.52 Favored 'General case' 0 N--CA 1.514 2.742 0 O-C-N 122.12 -0.362 . . . . 0.0 111.341 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 49.63 -94.79 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.777 0 C-N-CA 123.527 0.731 . . . . 0.0 111.075 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -129.39 50.72 0.88 Allowed Glycine 0 N--CA 1.503 3.15 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 178.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . 0.484 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 16.6 t80 72.42 69.5 0.14 Allowed 'General case' 0 N--CA 1.506 2.364 0 CA-C-O 121.84 0.829 . . . . 0.0 109.768 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.1 pp -133.79 153.77 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.687 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -63.92 104.32 0.69 Allowed 'General case' 0 N--CA 1.511 2.61 0 CA-C-O 121.578 0.704 . . . . 0.0 111.76 -177.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.77 167.88 12.93 Favored 'General case' 0 N--CA 1.517 2.905 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -68.67 -172.92 0.4 Allowed 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.538 -0.726 . . . . 0.0 111.131 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . 0.46 HG12 ' HB2' ' A' ' 426' ' ' GLU . 2.6 tt -105.8 -54.19 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.68 0 O-C-N 121.66 -0.65 . . . . 0.0 110.929 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 53.31 48.36 22.2 Favored 'General case' 0 N--CA 1.512 2.659 0 CA-C-O 121.458 0.647 . . . . 0.0 111.168 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . 0.46 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.512 2.629 0 O-C-N 121.81 -0.556 . . . . 0.0 109.969 179.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.552 1.048 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . 0.441 ' HG2' ' CD2' ' A' ' 413' ' ' TYR . 33.9 Cg_endo -76.44 170.26 20.31 Favored 'Trans proline' 0 CA--C 1.553 1.457 0 C-N-CA 122.695 2.263 . . . . 0.0 112.385 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -49.19 132.36 19.58 Favored 'General case' 0 N--CA 1.518 2.928 0 CA-C-O 121.05 0.452 . . . . 0.0 111.55 -179.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.1 -43.49 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -178.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . 0.441 ' CD2' ' HG2' ' A' ' 410' ' ' PRO . 97.2 m-85 -76.15 83.95 2.98 Favored 'General case' 0 N--CA 1.503 2.191 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.32 153.97 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.135 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.672 -178.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.5 OUTLIER -96.28 116.82 29.62 Favored 'General case' 0 N--CA 1.505 2.323 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.491 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -170.73 2.81 Favored 'General case' 0 N--CA 1.513 2.706 0 O-C-N 121.824 -0.547 . . . . 0.0 111.027 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -50.95 127.95 20.07 Favored 'General case' 0 N--CA 1.511 2.598 0 CA-C-O 121.353 0.597 . . . . 0.0 110.75 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 92.75 -0.37 70.08 Favored Glycine 0 N--CA 1.505 3.242 0 CA-C-O 118.57 -1.128 . . . . 0.0 112.187 -179.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 33.6 t80 66.89 70.07 0.39 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-N 119.785 1.792 . . . . 0.0 109.196 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 415' ' ' LEU . 2.1 pp -134.4 152.33 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.543 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 56.9 m -70.05 97.99 1.24 Allowed 'General case' 0 N--CA 1.508 2.452 0 N-CA-C 112.523 0.564 . . . . 0.0 112.523 -177.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.22 -170.62 3.13 Favored 'General case' 0 N--CA 1.516 2.858 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -72.86 -178.63 2.82 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.075 -1.015 . . . . 0.0 111.354 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . 0.455 HG12 ' HB2' ' A' ' 426' ' ' GLU . 5.8 tt -109.78 -52.85 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.682 0 O-C-N 121.924 -0.485 . . . . 0.0 110.867 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 58.32 63.03 1.83 Allowed 'General case' 0 N--CA 1.511 2.603 0 CA-C-O 121.687 0.756 . . . . 0.0 110.511 179.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . 0.455 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.511 2.613 0 O-C-N 122.028 -0.42 . . . . 0.0 110.169 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 11.9 m . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . 0.426 ' HG2' ' CD1' ' A' ' 413' ' ' TYR . 33.4 Cg_endo -76.31 -179.29 5.13 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.84 2.36 . . . . 0.0 112.879 -179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -50.25 132.07 24.06 Favored 'General case' 0 N--CA 1.519 3.018 0 CA-C-O 121.002 0.43 . . . . 0.0 111.395 -179.257 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.05 -45.25 1.81 Allowed Glycine 0 N--CA 1.508 3.48 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -178.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . 0.426 ' CD1' ' HG2' ' A' ' 410' ' ' PRO . 13.9 m-85 -83.06 88.27 6.88 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.2 -172.59 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.316 0 O-C-N 121.584 -0.698 . . . . 0.0 111.311 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -95.73 126.64 41.14 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . 0.491 ' HB2' HD13 ' A' ' 420' ' ' ILE . 0.5 OUTLIER -75.35 -173.6 2.12 Favored 'General case' 0 N--CA 1.515 2.775 0 O-C-N 121.979 -0.451 . . . . 0.0 110.758 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -53.97 -34.04 58.64 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 121.678 -0.639 . . . . 0.0 111.125 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -88.95 10.39 72.95 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 118.808 -0.995 . . . . 0.0 112.542 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 12.2 t80 61.05 60.64 1.77 Allowed 'General case' 0 N--CA 1.508 2.466 0 CA-C-N 119.726 1.763 . . . . 0.0 110.038 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . 0.491 HD13 ' HB2' ' A' ' 416' ' ' ASP . 2.1 pp -138.35 159.32 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.667 0 O-C-N 121.779 -0.575 . . . . 0.0 109.636 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.1 t -64.65 103.96 0.75 Allowed 'General case' 0 N--CA 1.512 2.628 0 CA-C-O 121.48 0.657 . . . . 0.0 111.13 -178.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.8 m -86.21 166.12 15.97 Favored 'General case' 0 N--CA 1.514 2.756 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -65.76 -172.52 0.13 Allowed 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 121.345 0.593 . . . . 0.0 110.795 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -78.57 -33.08 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.653 0 O-C-N 121.538 -0.726 . . . . 0.0 110.13 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 54.74 46.72 24.03 Favored 'General case' 0 N--CA 1.514 2.729 0 CA-C-O 121.656 0.741 . . . . 0.0 110.25 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 . . . . . 0 N--CA 1.507 2.424 0 O-C-N 122.042 -0.412 . . . . 0.0 110.231 -179.811 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.552 1.042 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -76.92 -176.41 3.16 Favored 'Trans proline' 0 CA--C 1.556 1.585 0 C-N-CA 122.627 2.218 . . . . 0.0 112.214 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -51.49 131.82 29.44 Favored 'General case' 0 N--CA 1.517 2.883 0 CA-C-O 121.003 0.43 . . . . 0.0 111.251 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.35 -40.16 2.56 Favored Glycine 0 N--CA 1.507 3.394 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . 0.45 ' HA ' HD13 ' A' ' 424' ' ' ILE . 82.0 m-85 -83.47 84.99 7.32 Favored 'General case' 0 N--CA 1.5 2.037 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 6.1 pt -83.01 173.42 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.519 3.007 0 CA-C-O 121.463 0.649 . . . . 0.0 111.749 -178.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -100.85 154.05 18.97 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-O 121.209 0.528 . . . . 0.0 109.888 179.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.7 -168.14 3.02 Favored 'General case' 0 N--CA 1.51 2.572 0 O-C-N 122.085 -0.384 . . . . 0.0 110.864 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 54.94 -90.79 0.03 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.319 0.648 . . . . 0.0 110.66 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -131.57 46.27 1.08 Allowed Glycine 0 N--CA 1.503 3.104 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 28.8 t80 70.65 67.3 0.19 Allowed 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 122.135 0.969 . . . . 0.0 109.254 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.2 pp -138.96 156.18 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.719 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.971 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.6 t -62.04 118.48 7.36 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 122.086 -0.384 . . . . 0.0 110.752 -179.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 85.9 m -109.3 139.31 44.41 Favored 'General case' 0 N--CA 1.508 2.472 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -74.89 -174.78 2.31 Favored 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.478 0.656 . . . . 0.0 111.346 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . 0.45 HD13 ' HA ' ' A' ' 413' ' ' TYR . 2.2 mm -121.38 -147.46 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.371 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -115.81 39.4 3.04 Favored 'General case' 0 N--CA 1.505 2.324 0 O-C-N 121.296 -0.877 . . . . 0.0 108.983 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 . . . . . 0 N--CA 1.508 2.453 0 O-C-N 122.019 -0.426 . . . . 0.0 110.076 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.557 1.248 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -77.14 -167.8 0.51 Allowed 'Trans proline' 0 N--CA 1.5 1.908 0 C-N-CA 123.247 2.631 . . . . 0.0 112.471 -179.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -47.54 131.0 14.19 Favored 'General case' 0 N--CA 1.521 3.081 0 CA-C-O 121.002 0.429 . . . . 0.0 111.125 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.47 -48.53 1.69 Allowed Glycine 0 N--CA 1.509 3.546 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 -177.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -82.88 86.49 6.93 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.98 -168.51 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.366 0 O-C-N 121.498 -0.751 . . . . 0.0 112.691 -176.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.406 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -106.1 141.13 37.98 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -133.8 -175.51 3.86 Favored 'General case' 0 N--CA 1.516 2.871 0 O-C-N 121.873 -0.517 . . . . 0.0 111.469 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 51.19 -96.65 0.05 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.352 0.661 . . . . 0.0 110.905 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -124.57 48.2 0.97 Allowed Glycine 0 N--CA 1.502 3.083 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . 0.406 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 17.8 t80 70.84 70.9 0.19 Allowed 'General case' 0 N--CA 1.505 2.306 0 CA-C-O 121.917 0.865 . . . . 0.0 109.801 -179.271 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.1 pp -132.88 151.35 34.18 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.621 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.88 116.81 4.02 Favored 'General case' 0 N--CA 1.514 2.766 0 CA-C-O 121.402 0.62 . . . . 0.0 111.904 -177.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 31.0 m -123.41 152.05 41.99 Favored 'General case' 0 N--CA 1.51 2.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.27 -162.56 0.3 Allowed 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.454 0.645 . . . . 0.0 111.252 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 1.1 tt -81.42 -35.74 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.928 -0.483 . . . . 0.0 110.294 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 53.86 55.98 7.73 Favored 'General case' 0 N--CA 1.51 2.562 0 CA-C-O 121.421 0.629 . . . . 0.0 110.146 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 N--CA 1.521 3.099 0 C-N-CA 123.879 0.872 . . . . 0.0 110.423 -179.537 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 10.8 m . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -76.95 -171.07 1.04 Allowed 'Trans proline' 0 N--CA 1.499 1.829 0 C-N-CA 123.003 2.469 . . . . 0.0 112.765 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.3 131.15 8.17 Favored 'General case' 0 N--CA 1.521 3.084 0 C-N-CA 122.806 0.442 . . . . 0.0 111.479 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -50.87 2.12 Favored Glycine 0 N--CA 1.504 3.208 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -177.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -78.49 87.34 4.48 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 414' ' ' ILE . . . . . 0.42 HD12 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -102.8 -170.67 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.153 0 O-C-N 121.53 -0.731 . . . . 0.0 110.984 -178.602 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 415' ' ' LEU . . . . . 0.5 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -100.55 123.1 44.3 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 416' ' ' ASP . . . . . 0.492 ' HB2' HD13 ' A' ' 420' ' ' ILE . 0.4 OUTLIER -74.94 -169.45 0.91 Allowed 'General case' 0 N--CA 1.517 2.883 0 O-C-N 121.923 -0.486 . . . . 0.0 111.097 -179.657 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -51.98 -37.75 54.2 Favored 'General case' 0 N--CA 1.519 3.01 0 O-C-N 121.728 -0.608 . . . . 0.0 111.878 -179.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -91.05 14.18 64.19 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 119.002 -0.888 . . . . 0.0 112.209 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 419' ' ' PHE . . . . . 0.5 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 10.8 t80 58.3 62.55 1.97 Allowed 'General case' 0 N--CA 1.506 2.33 0 CA-C-N 119.347 1.574 . . . . 0.0 110.08 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 420' ' ' ILE . . . . . 0.492 HD13 ' HB2' ' A' ' 416' ' ' ASP . 2.1 pp -135.65 159.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.511 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.686 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.3 t -65.7 102.84 0.79 Allowed 'General case' 0 N--CA 1.511 2.604 0 CA-C-O 121.464 0.65 . . . . 0.0 111.167 -178.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 422' ' ' THR . . . . . 0.42 ' HB ' HD12 ' A' ' 414' ' ' ILE . 7.8 m -84.53 168.41 15.44 Favored 'General case' 0 N--CA 1.514 2.75 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -64.81 -171.75 0.07 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 121.585 -0.697 . . . . 0.0 110.589 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -81.98 -41.82 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.597 0 O-C-N 121.324 -0.86 . . . . 0.0 109.823 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 51.97 46.02 27.29 Favored 'General case' 0 N--CA 1.512 2.665 0 CA-C-O 121.525 0.678 . . . . 0.0 111.064 178.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.91 -0.494 . . . . 0.0 110.032 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . 0.463 ' HB3' ' CB ' ' A' ' 413' ' ' TYR . 15.3 m . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -77.77 -172.9 1.61 Allowed 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.956 2.437 . . . . 0.0 112.731 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.26 134.23 23.02 Favored 'General case' 0 N--CA 1.518 2.961 0 CA-C-O 121.031 0.443 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.38 -43.87 2.05 Favored Glycine 0 N--CA 1.509 3.517 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . 0.463 ' CB ' ' HB3' ' A' ' 409' ' ' CYS . 51.3 m-85 -84.89 87.44 7.34 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.81 -176.32 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.14 0 O-C-N 121.582 -0.699 . . . . 0.0 111.715 -177.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.563 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.1 mm? -103.1 116.87 33.34 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.5 -172.17 2.5 Favored 'General case' 0 N--CA 1.512 2.636 0 O-C-N 122.097 -0.377 . . . . 0.0 110.766 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 56.8 -87.25 0.02 OUTLIER 'General case' 0 N--CA 1.513 2.701 0 C-N-CA 123.233 0.613 . . . . 0.0 110.289 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -133.38 44.58 1.18 Allowed Glycine 0 N--CA 1.502 3.078 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 178.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . 0.563 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 18.6 t80 70.51 64.97 0.2 Allowed 'General case' 0 N--CA 1.505 2.315 0 CA-C-O 121.992 0.901 . . . . 0.0 109.491 -179.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.2 pp -135.28 152.53 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.713 0 O-C-N 121.865 -0.522 . . . . 0.0 109.858 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.1 m -62.02 109.2 1.21 Allowed 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 121.242 0.544 . . . . 0.0 110.108 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.4 m -91.0 149.27 21.91 Favored 'General case' 0 N--CA 1.512 2.651 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.342 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -74.67 -173.35 1.79 Allowed 'General case' 0 N--CA 1.503 2.221 0 CA-C-O 121.231 0.538 . . . . 0.0 110.992 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . 0.654 HG12 ' OXT' ' A' ' 426' ' ' GLU . 11.8 tt -174.78 -50.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.886 0 O-C-N 121.884 -0.51 . . . . 0.0 110.99 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 61.93 58.26 1.95 Allowed 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . 0.654 ' OXT' HG12 ' A' ' 424' ' ' ILE . 1.1 mp0 . . . . . 0 N--CA 1.521 3.081 0 C-N-CA 123.962 0.905 . . . . 0.0 110.658 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.556 1.189 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.53 179.05 6.8 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.857 2.371 . . . . 0.0 112.866 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -46.73 133.91 10.21 Favored 'General case' 0 N--CA 1.521 3.083 0 CA-C-O 121.106 0.479 . . . . 0.0 111.271 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 95.38 -49.28 1.89 Allowed Glycine 0 N--CA 1.507 3.397 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 -177.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -81.14 88.42 6.0 Favored 'General case' 0 N--CA 1.499 2.006 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 178.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . 0.439 HD12 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -95.39 -176.35 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.28 0 O-C-N 121.522 -0.737 . . . . 0.0 110.417 -178.857 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.2 OUTLIER -104.98 139.01 40.31 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.591 -0.693 . . . . 0.0 109.414 179.704 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.51 -173.54 2.5 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -54.07 119.25 4.82 Favored 'General case' 0 N--CA 1.515 2.799 0 CA-C-O 121.113 0.482 . . . . 0.0 110.399 -179.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.13 -4.44 31.7 Favored Glycine 0 N--CA 1.506 3.34 0 CA-C-O 118.775 -1.014 . . . . 0.0 111.862 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 22.7 t80 68.15 66.86 0.34 Allowed 'General case' 0 N--CA 1.508 2.428 0 CA-C-N 119.505 1.652 . . . . 0.0 109.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 415' ' ' LEU . 2.1 pp -135.79 152.83 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.575 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.7 t -70.93 115.75 10.43 Favored 'General case' 0 N--CA 1.511 2.614 0 CA-C-O 121.398 0.618 . . . . 0.0 111.764 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 422' ' ' THR . . . . . 0.439 ' HB ' HD12 ' A' ' 414' ' ' ILE . 1.7 m -96.63 162.9 13.25 Favored 'General case' 0 N--CA 1.513 2.685 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -63.32 -173.8 0.07 Allowed 'General case' 0 N--CA 1.504 2.264 0 CA-C-O 121.644 0.735 . . . . 0.0 110.971 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -79.63 -34.63 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 121.509 -0.744 . . . . 0.0 109.876 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 57.71 52.32 8.34 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-O 121.771 0.796 . . . . 0.0 110.168 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.507 2.386 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.878 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 CA--C 1.556 1.2 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -75.68 -168.97 0.59 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.982 2.455 . . . . 0.0 112.477 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -47.11 130.4 12.59 Favored 'General case' 0 N--CA 1.519 2.99 0 CA-C-O 121.031 0.443 . . . . 0.0 111.183 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.71 -49.05 1.46 Allowed Glycine 0 N--CA 1.508 3.475 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -177.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -80.7 88.57 5.76 Favored 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -86.95 -172.97 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.338 0 CA-C-O 121.352 0.596 . . . . 0.0 112.474 -176.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.431 HD21 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -104.44 153.96 20.46 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.853 -0.53 . . . . 0.0 109.925 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . 0.433 ' HB2' ' OG1' ' A' ' 422' ' ' THR . 0.4 OUTLIER -106.25 -171.54 1.92 Allowed 'General case' 0 N--CA 1.514 2.766 0 O-C-N 121.937 -0.477 . . . . 0.0 111.003 179.623 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -51.29 130.17 26.24 Favored 'General case' 0 N--CA 1.515 2.789 0 CA-C-O 121.16 0.505 . . . . 0.0 110.855 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 96.81 -6.12 64.43 Favored Glycine 0 N--CA 1.507 3.409 0 CA-C-O 119.036 -0.869 . . . . 0.0 111.453 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 25.9 t80 68.43 71.41 0.3 Allowed 'General case' 0 N--CA 1.509 2.479 0 CA-C-N 119.092 1.446 . . . . 0.0 109.229 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.6 153.94 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.497 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.718 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . 0.431 ' HA ' HD21 ' A' ' 415' ' ' LEU . 0.1 OUTLIER -60.0 124.98 21.9 Favored 'General case' 0 N--CA 1.516 2.848 0 CA-C-O 121.013 0.435 . . . . 0.0 111.382 -178.623 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 422' ' ' THR . . . . . 0.433 ' OG1' ' HB2' ' A' ' 416' ' ' ASP . 6.5 m -134.3 150.03 50.94 Favored 'General case' 0 N--CA 1.509 2.506 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -91.82 143.61 26.34 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 122.405 1.098 . . . . 0.0 111.04 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 20.9 tt -55.04 -37.06 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.921 178.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 55.25 53.43 10.05 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-O 121.692 0.758 . . . . 0.0 110.416 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.478 0 O-C-N 121.931 -0.481 . . . . 0.0 110.045 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 1.2 m . . . . . 0 CA--C 1.558 1.288 0 N-CA-C 110.61 -0.144 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -76.17 177.84 8.25 Favored 'Trans proline' 0 N--CA 1.496 1.676 0 C-N-CA 123.007 2.471 . . . . 0.0 113.282 -178.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.82 134.02 25.75 Favored 'General case' 0 N--CA 1.518 2.959 0 CA-C-O 121.032 0.444 . . . . 0.0 111.194 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.49 -43.81 2.31 Favored Glycine 0 N--CA 1.508 3.484 0 N-CA-C 108.761 -1.735 . . . . 0.0 108.761 -177.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . 0.488 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 74.6 m-85 -85.74 75.77 10.03 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 2.1 pt -67.08 172.69 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.527 3.413 0 O-C-N 121.568 -0.708 . . . . 0.0 112.32 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -105.48 119.74 39.87 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . 0.4 ' CB ' HD13 ' A' ' 420' ' ' ILE . 0.1 OUTLIER -82.98 -170.56 3.09 Favored 'General case' 0 N--CA 1.514 2.77 0 O-C-N 122.004 -0.435 . . . . 0.0 111.416 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -49.44 123.01 6.86 Favored 'General case' 0 N--CA 1.516 2.839 0 CA-C-O 121.202 0.525 . . . . 0.0 110.866 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 95.03 -0.24 64.16 Favored Glycine 0 N--CA 1.507 3.382 0 CA-C-O 118.909 -0.939 . . . . 0.0 111.794 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 20.6 t80 66.44 71.44 0.4 Allowed 'General case' 0 N--CA 1.506 2.352 0 CA-C-N 119.306 1.553 . . . . 0.0 109.34 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . 0.4 HD13 ' CB ' ' A' ' 416' ' ' ASP . 2.1 pp -133.15 151.0 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.479 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.3 m -63.74 104.1 0.63 Allowed 'General case' 0 N--CA 1.511 2.607 0 CA-C-O 121.532 0.682 . . . . 0.0 112.681 -176.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 3.5 m -89.19 155.41 19.43 Favored 'General case' 0 N--CA 1.516 2.861 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.57 -171.57 0.28 Allowed 'General case' 0 N--CA 1.506 2.347 0 CA-C-O 121.455 0.645 . . . . 0.0 111.457 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 3.6 tt -115.84 -139.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.283 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 64.16 83.0 0.17 Allowed 'General case' 0 N--CA 1.512 2.649 0 CA-C-N 120.064 1.302 . . . . 0.0 110.131 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.522 3.143 0 C-N-CA 123.722 0.809 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 22.3 m . . . . . 0 CA--C 1.556 1.199 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.92 -174.57 2.23 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 122.866 2.378 . . . . 0.0 112.764 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.99 132.44 9.34 Favored 'General case' 0 N--CA 1.52 3.052 0 C-N-CA 122.756 0.422 . . . . 0.0 111.492 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -49.59 2.13 Favored Glycine 0 N--CA 1.505 3.236 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -178.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 37.4 m-85 -77.41 85.68 3.81 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.27 -172.86 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.521 3.081 0 O-C-N 121.778 -0.576 . . . . 0.0 110.805 -178.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.9 OUTLIER -104.13 121.18 42.7 Favored 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.28 -174.41 5.21 Favored 'General case' 0 N--CA 1.512 2.657 0 O-C-N 121.956 -0.465 . . . . 0.0 111.1 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -54.01 116.43 2.56 Favored 'General case' 0 N--CA 1.513 2.717 0 CA-C-O 121.215 0.531 . . . . 0.0 110.124 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.57 -3.93 30.92 Favored Glycine 0 N--CA 1.507 3.368 0 CA-C-O 118.773 -1.015 . . . . 0.0 111.776 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 21.0 t80 68.26 69.21 0.32 Allowed 'General case' 0 N--CA 1.505 2.286 0 CA-C-N 119.49 1.645 . . . . 0.0 109.916 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 415' ' ' LEU . 2.1 pp -139.09 151.99 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.501 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.8 t -71.11 114.17 8.9 Favored 'General case' 0 N--CA 1.512 2.652 0 O-C-N 121.613 -0.679 . . . . 0.0 110.689 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.17 -173.92 3.07 Favored 'General case' 0 N--CA 1.516 2.863 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.24 -172.2 0.87 Allowed 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.623 -0.673 . . . . 0.0 111.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . 0.418 HG12 ' HB2' ' A' ' 426' ' ' GLU . 0.4 OUTLIER -84.91 -41.25 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.766 -0.583 . . . . 0.0 110.015 -179.903 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 53.59 47.19 24.46 Favored 'General case' 0 N--CA 1.511 2.623 0 CA-C-O 121.531 0.681 . . . . 0.0 111.027 178.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . 0.418 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.871 -0.518 . . . . 0.0 110.113 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 CA--C 1.557 1.232 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -76.92 -170.7 0.96 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 123.009 2.472 . . . . 0.0 112.605 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -47.2 130.21 12.8 Favored 'General case' 0 N--CA 1.521 3.086 0 CA-C-O 120.878 0.37 . . . . 0.0 111.063 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . 0.451 ' HA3' HG13 ' A' ' 424' ' ' ILE . . . 95.27 -48.73 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -78.71 86.65 4.65 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 8.4 pt -89.7 -170.93 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.166 0 O-C-N 121.565 -0.71 . . . . 0.0 111.523 -178.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.484 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -111.86 120.57 42.41 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.45 -173.94 2.52 Favored 'General case' 0 N--CA 1.514 2.742 0 O-C-N 122.12 -0.362 . . . . 0.0 111.341 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 49.63 -94.79 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.777 0 C-N-CA 123.527 0.731 . . . . 0.0 111.075 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -129.39 50.72 0.88 Allowed Glycine 0 N--CA 1.503 3.15 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 178.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . 0.484 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 16.6 t80 72.42 69.5 0.14 Allowed 'General case' 0 N--CA 1.506 2.364 0 CA-C-O 121.84 0.829 . . . . 0.0 109.768 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.1 pp -133.79 153.77 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.687 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 178.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -63.92 104.32 0.69 Allowed 'General case' 0 N--CA 1.511 2.61 0 CA-C-O 121.578 0.704 . . . . 0.0 111.76 -177.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.77 167.88 12.93 Favored 'General case' 0 N--CA 1.517 2.905 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -68.67 -172.92 0.4 Allowed 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.538 -0.726 . . . . 0.0 111.131 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . 0.46 HG12 ' HB2' ' A' ' 426' ' ' GLU . 2.6 tt -105.8 -54.19 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.68 0 O-C-N 121.66 -0.65 . . . . 0.0 110.929 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 53.31 48.36 22.2 Favored 'General case' 0 N--CA 1.512 2.659 0 CA-C-O 121.458 0.647 . . . . 0.0 111.168 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . 0.46 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.512 2.629 0 O-C-N 121.81 -0.556 . . . . 0.0 109.969 179.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.552 1.048 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . 0.441 ' HG2' ' CD2' ' A' ' 413' ' ' TYR . 33.9 Cg_endo -76.44 170.26 20.31 Favored 'Trans proline' 0 CA--C 1.553 1.457 0 C-N-CA 122.695 2.263 . . . . 0.0 112.385 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -49.19 132.36 19.58 Favored 'General case' 0 N--CA 1.518 2.928 0 CA-C-O 121.05 0.452 . . . . 0.0 111.55 -179.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.1 -43.49 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -178.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . 0.441 ' CD2' ' HG2' ' A' ' 410' ' ' PRO . 97.2 m-85 -76.15 83.95 2.98 Favored 'General case' 0 N--CA 1.503 2.191 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.32 153.97 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.135 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.672 -178.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.5 OUTLIER -96.28 116.82 29.62 Favored 'General case' 0 N--CA 1.505 2.323 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.491 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -170.73 2.81 Favored 'General case' 0 N--CA 1.513 2.706 0 O-C-N 121.824 -0.547 . . . . 0.0 111.027 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -50.95 127.95 20.07 Favored 'General case' 0 N--CA 1.511 2.598 0 CA-C-O 121.353 0.597 . . . . 0.0 110.75 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 92.75 -0.37 70.08 Favored Glycine 0 N--CA 1.505 3.242 0 CA-C-O 118.57 -1.128 . . . . 0.0 112.187 -179.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 33.6 t80 66.89 70.07 0.39 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-N 119.785 1.792 . . . . 0.0 109.196 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 415' ' ' LEU . 2.1 pp -134.4 152.33 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.543 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 56.9 m -70.05 97.99 1.24 Allowed 'General case' 0 N--CA 1.508 2.452 0 N-CA-C 112.523 0.564 . . . . 0.0 112.523 -177.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.22 -170.62 3.13 Favored 'General case' 0 N--CA 1.516 2.858 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -72.86 -178.63 2.82 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.075 -1.015 . . . . 0.0 111.354 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . 0.455 HG12 ' HB2' ' A' ' 426' ' ' GLU . 5.8 tt -109.78 -52.85 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.682 0 O-C-N 121.924 -0.485 . . . . 0.0 110.867 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 58.32 63.03 1.83 Allowed 'General case' 0 N--CA 1.511 2.603 0 CA-C-O 121.687 0.756 . . . . 0.0 110.511 179.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . 0.455 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.511 2.613 0 O-C-N 122.028 -0.42 . . . . 0.0 110.169 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 11.9 m . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . 0.426 ' HG2' ' CD1' ' A' ' 413' ' ' TYR . 33.4 Cg_endo -76.31 -179.29 5.13 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.84 2.36 . . . . 0.0 112.879 -179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -50.25 132.07 24.06 Favored 'General case' 0 N--CA 1.519 3.018 0 CA-C-O 121.002 0.43 . . . . 0.0 111.395 -179.257 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.05 -45.25 1.81 Allowed Glycine 0 N--CA 1.508 3.48 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -178.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . 0.426 ' CD1' ' HG2' ' A' ' 410' ' ' PRO . 13.9 m-85 -83.06 88.27 6.88 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.2 -172.59 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.316 0 O-C-N 121.584 -0.698 . . . . 0.0 111.311 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -95.73 126.64 41.14 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . 0.491 ' HB2' HD13 ' A' ' 420' ' ' ILE . 0.5 OUTLIER -75.35 -173.6 2.12 Favored 'General case' 0 N--CA 1.515 2.775 0 O-C-N 121.979 -0.451 . . . . 0.0 110.758 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -53.97 -34.04 58.64 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 121.678 -0.639 . . . . 0.0 111.125 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -88.95 10.39 72.95 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 118.808 -0.995 . . . . 0.0 112.542 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 12.2 t80 61.05 60.64 1.77 Allowed 'General case' 0 N--CA 1.508 2.466 0 CA-C-N 119.726 1.763 . . . . 0.0 110.038 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . 0.491 HD13 ' HB2' ' A' ' 416' ' ' ASP . 2.1 pp -138.35 159.32 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.667 0 O-C-N 121.779 -0.575 . . . . 0.0 109.636 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.1 t -64.65 103.96 0.75 Allowed 'General case' 0 N--CA 1.512 2.628 0 CA-C-O 121.48 0.657 . . . . 0.0 111.13 -178.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.8 m -86.21 166.12 15.97 Favored 'General case' 0 N--CA 1.514 2.756 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -65.76 -172.52 0.13 Allowed 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 121.345 0.593 . . . . 0.0 110.795 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -78.57 -33.08 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.653 0 O-C-N 121.538 -0.726 . . . . 0.0 110.13 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 54.74 46.72 24.03 Favored 'General case' 0 N--CA 1.514 2.729 0 CA-C-O 121.656 0.741 . . . . 0.0 110.25 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 . . . . . 0 N--CA 1.507 2.424 0 O-C-N 122.042 -0.412 . . . . 0.0 110.231 -179.811 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.552 1.042 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -76.92 -176.41 3.16 Favored 'Trans proline' 0 CA--C 1.556 1.585 0 C-N-CA 122.627 2.218 . . . . 0.0 112.214 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -51.49 131.82 29.44 Favored 'General case' 0 N--CA 1.517 2.883 0 CA-C-O 121.003 0.43 . . . . 0.0 111.251 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.35 -40.16 2.56 Favored Glycine 0 N--CA 1.507 3.394 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . 0.45 ' HA ' HD13 ' A' ' 424' ' ' ILE . 82.0 m-85 -83.47 84.99 7.32 Favored 'General case' 0 N--CA 1.5 2.037 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 6.1 pt -83.01 173.42 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.519 3.007 0 CA-C-O 121.463 0.649 . . . . 0.0 111.749 -178.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -100.85 154.05 18.97 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-O 121.209 0.528 . . . . 0.0 109.888 179.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.7 -168.14 3.02 Favored 'General case' 0 N--CA 1.51 2.572 0 O-C-N 122.085 -0.384 . . . . 0.0 110.864 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 54.94 -90.79 0.03 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.319 0.648 . . . . 0.0 110.66 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -131.57 46.27 1.08 Allowed Glycine 0 N--CA 1.503 3.104 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 28.8 t80 70.65 67.3 0.19 Allowed 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 122.135 0.969 . . . . 0.0 109.254 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.2 pp -138.96 156.18 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.719 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.971 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.6 t -62.04 118.48 7.36 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 122.086 -0.384 . . . . 0.0 110.752 -179.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 85.9 m -109.3 139.31 44.41 Favored 'General case' 0 N--CA 1.508 2.472 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -74.89 -174.78 2.31 Favored 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.478 0.656 . . . . 0.0 111.346 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . 0.45 HD13 ' HA ' ' A' ' 413' ' ' TYR . 2.2 mm -121.38 -147.46 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.371 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -115.81 39.4 3.04 Favored 'General case' 0 N--CA 1.505 2.324 0 O-C-N 121.296 -0.877 . . . . 0.0 108.983 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 . . . . . 0 N--CA 1.508 2.453 0 O-C-N 122.019 -0.426 . . . . 0.0 110.076 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.557 1.248 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -77.14 -167.8 0.51 Allowed 'Trans proline' 0 N--CA 1.5 1.908 0 C-N-CA 123.247 2.631 . . . . 0.0 112.471 -179.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -47.54 131.0 14.19 Favored 'General case' 0 N--CA 1.521 3.081 0 CA-C-O 121.002 0.429 . . . . 0.0 111.125 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.47 -48.53 1.69 Allowed Glycine 0 N--CA 1.509 3.546 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 -177.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -82.88 86.49 6.93 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.98 -168.51 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.366 0 O-C-N 121.498 -0.751 . . . . 0.0 112.691 -176.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.406 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -106.1 141.13 37.98 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -133.8 -175.51 3.86 Favored 'General case' 0 N--CA 1.516 2.871 0 O-C-N 121.873 -0.517 . . . . 0.0 111.469 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 51.19 -96.65 0.05 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.352 0.661 . . . . 0.0 110.905 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -124.57 48.2 0.97 Allowed Glycine 0 N--CA 1.502 3.083 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . 0.406 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 17.8 t80 70.84 70.9 0.19 Allowed 'General case' 0 N--CA 1.505 2.306 0 CA-C-O 121.917 0.865 . . . . 0.0 109.801 -179.271 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . . . . . . . . . 2.1 pp -132.88 151.35 34.18 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.621 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.88 116.81 4.02 Favored 'General case' 0 N--CA 1.514 2.766 0 CA-C-O 121.402 0.62 . . . . 0.0 111.904 -177.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 31.0 m -123.41 152.05 41.99 Favored 'General case' 0 N--CA 1.51 2.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.27 -162.56 0.3 Allowed 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.454 0.645 . . . . 0.0 111.252 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 1.1 tt -81.42 -35.74 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.928 -0.483 . . . . 0.0 110.294 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 53.86 55.98 7.73 Favored 'General case' 0 N--CA 1.51 2.562 0 CA-C-O 121.421 0.629 . . . . 0.0 110.146 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 N--CA 1.521 3.099 0 C-N-CA 123.879 0.872 . . . . 0.0 110.423 -179.537 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 10.8 m . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -76.95 -171.07 1.04 Allowed 'Trans proline' 0 N--CA 1.499 1.829 0 C-N-CA 123.003 2.469 . . . . 0.0 112.765 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.3 131.15 8.17 Favored 'General case' 0 N--CA 1.521 3.084 0 C-N-CA 122.806 0.442 . . . . 0.0 111.479 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -50.87 2.12 Favored Glycine 0 N--CA 1.504 3.208 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -177.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -78.49 87.34 4.48 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 414' ' ' ILE . . . . . 0.42 HD12 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -102.8 -170.67 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.153 0 O-C-N 121.53 -0.731 . . . . 0.0 110.984 -178.602 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 415' ' ' LEU . . . . . 0.5 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -100.55 123.1 44.3 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 416' ' ' ASP . . . . . 0.492 ' HB2' HD13 ' A' ' 420' ' ' ILE . 0.4 OUTLIER -74.94 -169.45 0.91 Allowed 'General case' 0 N--CA 1.517 2.883 0 O-C-N 121.923 -0.486 . . . . 0.0 111.097 -179.657 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -51.98 -37.75 54.2 Favored 'General case' 0 N--CA 1.519 3.01 0 O-C-N 121.728 -0.608 . . . . 0.0 111.878 -179.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -91.05 14.18 64.19 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 119.002 -0.888 . . . . 0.0 112.209 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 419' ' ' PHE . . . . . 0.5 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 10.8 t80 58.3 62.55 1.97 Allowed 'General case' 0 N--CA 1.506 2.33 0 CA-C-N 119.347 1.574 . . . . 0.0 110.08 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 420' ' ' ILE . . . . . 0.492 HD13 ' HB2' ' A' ' 416' ' ' ASP . 2.1 pp -135.65 159.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.511 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.686 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.3 t -65.7 102.84 0.79 Allowed 'General case' 0 N--CA 1.511 2.604 0 CA-C-O 121.464 0.65 . . . . 0.0 111.167 -178.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 422' ' ' THR . . . . . 0.42 ' HB ' HD12 ' A' ' 414' ' ' ILE . 7.8 m -84.53 168.41 15.44 Favored 'General case' 0 N--CA 1.514 2.75 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -64.81 -171.75 0.07 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 121.585 -0.697 . . . . 0.0 110.589 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -81.98 -41.82 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.597 0 O-C-N 121.324 -0.86 . . . . 0.0 109.823 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 51.97 46.02 27.29 Favored 'General case' 0 N--CA 1.512 2.665 0 CA-C-O 121.525 0.678 . . . . 0.0 111.064 178.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.91 -0.494 . . . . 0.0 110.032 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 409' ' ' CYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 15.3 m . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -77.77 -172.9 1.61 Allowed 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.956 2.437 . . . . 0.0 112.731 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.26 134.23 23.02 Favored 'General case' 0 N--CA 1.518 2.961 0 CA-C-O 121.031 0.443 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.38 -43.87 2.05 Favored Glycine 0 N--CA 1.509 3.517 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 413' ' ' TYR . . . . . 0.466 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 51.3 m-85 -84.89 87.44 7.34 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.81 -176.32 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.14 0 O-C-N 121.582 -0.699 . . . . 0.0 111.715 -177.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.599 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.1 mm? -103.1 116.87 33.34 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.5 -172.17 2.5 Favored 'General case' 0 N--CA 1.512 2.636 0 O-C-N 122.097 -0.377 . . . . 0.0 110.766 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 56.8 -87.25 0.02 OUTLIER 'General case' 0 N--CA 1.513 2.701 0 C-N-CA 123.233 0.613 . . . . 0.0 110.289 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -133.38 44.58 1.18 Allowed Glycine 0 N--CA 1.502 3.078 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 178.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 419' ' ' PHE . . . . . 0.599 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 18.6 t80 70.51 64.97 0.2 Allowed 'General case' 0 N--CA 1.505 2.315 0 CA-C-O 121.992 0.901 . . . . 0.0 109.491 -179.15 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.591 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -135.28 152.53 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.713 0 O-C-N 121.865 -0.522 . . . . 0.0 109.858 179.279 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.1 m -62.02 109.2 1.21 Allowed 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 121.242 0.544 . . . . 0.0 110.108 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.4 m -91.0 149.27 21.91 Favored 'General case' 0 N--CA 1.512 2.651 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.342 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -74.67 -173.35 1.79 Allowed 'General case' 0 N--CA 1.503 2.221 0 CA-C-O 121.231 0.538 . . . . 0.0 110.992 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.659 HG12 ' OXT' ' A' ' 426' ' ' GLU . 11.8 tt -174.78 -50.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.886 0 O-C-N 121.884 -0.51 . . . . 0.0 110.99 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 425' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 424' ' ' ILE . 8.9 m-20 61.93 58.26 1.95 Allowed 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 426' ' ' GLU . . . . . 0.659 ' OXT' HG12 ' A' ' 424' ' ' ILE . 1.1 mp0 . . . . . 0 N--CA 1.521 3.081 0 C-N-CA 123.962 0.905 . . . . 0.0 110.658 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.556 1.189 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.53 179.05 6.8 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.857 2.371 . . . . 0.0 112.866 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -46.73 133.91 10.21 Favored 'General case' 0 N--CA 1.521 3.083 0 CA-C-O 121.106 0.479 . . . . 0.0 111.271 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 95.38 -49.28 1.89 Allowed Glycine 0 N--CA 1.507 3.397 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 -177.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -81.14 88.42 6.0 Favored 'General case' 0 N--CA 1.499 2.006 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 178.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.47 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -95.39 -176.35 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.28 0 O-C-N 121.522 -0.737 . . . . 0.0 110.417 -178.857 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.2 OUTLIER -104.98 139.01 40.31 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.591 -0.693 . . . . 0.0 109.414 179.704 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.51 -173.54 2.5 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -54.07 119.25 4.82 Favored 'General case' 0 N--CA 1.515 2.799 0 CA-C-O 121.113 0.482 . . . . 0.0 110.399 -179.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.13 -4.44 31.7 Favored Glycine 0 N--CA 1.506 3.34 0 CA-C-O 118.775 -1.014 . . . . 0.0 111.862 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 22.7 t80 68.15 66.86 0.34 Allowed 'General case' 0 N--CA 1.508 2.428 0 CA-C-N 119.505 1.652 . . . . 0.0 109.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.79 152.83 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.575 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.7 t -70.93 115.75 10.43 Favored 'General case' 0 N--CA 1.511 2.614 0 CA-C-O 121.398 0.618 . . . . 0.0 111.764 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 422' ' ' THR . . . . . 0.47 ' HB ' HD13 ' A' ' 414' ' ' ILE . 1.7 m -96.63 162.9 13.25 Favored 'General case' 0 N--CA 1.513 2.685 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -63.32 -173.8 0.07 Allowed 'General case' 0 N--CA 1.504 2.264 0 CA-C-O 121.644 0.735 . . . . 0.0 110.971 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -79.63 -34.63 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 121.509 -0.744 . . . . 0.0 109.876 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 57.71 52.32 8.34 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-O 121.771 0.796 . . . . 0.0 110.168 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.507 2.386 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.878 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 CA--C 1.556 1.2 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -75.68 -168.97 0.59 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.982 2.455 . . . . 0.0 112.477 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -47.11 130.4 12.59 Favored 'General case' 0 N--CA 1.519 2.99 0 CA-C-O 121.031 0.443 . . . . 0.0 111.183 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 412' ' ' GLY . . . . . 0.523 ' CA ' HD12 ' A' ' 424' ' ' ILE . . . 97.71 -49.05 1.46 Allowed Glycine 0 N--CA 1.508 3.475 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -80.7 88.57 5.76 Favored 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.469 HD13 ' C ' ' A' ' 414' ' ' ILE . 0.0 OUTLIER -86.95 -172.97 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.338 0 CA-C-O 121.352 0.596 . . . . 0.0 112.474 -176.784 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.595 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -104.44 153.96 20.46 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.853 -0.53 . . . . 0.0 109.925 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 416' ' ' ASP . . . . . 0.445 ' HB2' ' OG1' ' A' ' 422' ' ' THR . 0.4 OUTLIER -106.25 -171.54 1.92 Allowed 'General case' 0 N--CA 1.514 2.766 0 O-C-N 121.937 -0.477 . . . . 0.0 111.003 179.623 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -51.29 130.17 26.24 Favored 'General case' 0 N--CA 1.515 2.789 0 CA-C-O 121.16 0.505 . . . . 0.0 110.855 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 96.81 -6.12 64.43 Favored Glycine 0 N--CA 1.507 3.409 0 CA-C-O 119.036 -0.869 . . . . 0.0 111.453 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 25.9 t80 68.43 71.41 0.3 Allowed 'General case' 0 N--CA 1.509 2.479 0 CA-C-N 119.092 1.446 . . . . 0.0 109.229 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.509 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.0 pp -137.6 153.94 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.497 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.718 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 421' ' ' CYS . . . . . 0.595 ' HA ' HD22 ' A' ' 415' ' ' LEU . 0.1 OUTLIER -60.0 124.98 21.9 Favored 'General case' 0 N--CA 1.516 2.848 0 CA-C-O 121.013 0.435 . . . . 0.0 111.382 -178.623 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 422' ' ' THR . . . . . 0.445 ' OG1' ' HB2' ' A' ' 416' ' ' ASP . 6.5 m -134.3 150.03 50.94 Favored 'General case' 0 N--CA 1.509 2.506 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -91.82 143.61 26.34 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 122.405 1.098 . . . . 0.0 111.04 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.523 HD12 ' CA ' ' A' ' 412' ' ' GLY . 20.9 tt -55.04 -37.06 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.921 178.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 55.25 53.43 10.05 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-O 121.692 0.758 . . . . 0.0 110.416 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.478 0 O-C-N 121.931 -0.481 . . . . 0.0 110.045 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 409' ' ' CYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 1.2 m . . . . . 0 CA--C 1.558 1.288 0 N-CA-C 110.61 -0.144 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -76.17 177.84 8.25 Favored 'Trans proline' 0 N--CA 1.496 1.676 0 C-N-CA 123.007 2.471 . . . . 0.0 113.282 -178.569 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.82 134.02 25.75 Favored 'General case' 0 N--CA 1.518 2.959 0 CA-C-O 121.032 0.444 . . . . 0.0 111.194 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.49 -43.81 2.31 Favored Glycine 0 N--CA 1.508 3.484 0 N-CA-C 108.761 -1.735 . . . . 0.0 108.761 -177.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 413' ' ' TYR . . . . . 0.522 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 74.6 m-85 -85.74 75.77 10.03 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 2.1 pt -67.08 172.69 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.527 3.413 0 O-C-N 121.568 -0.708 . . . . 0.0 112.32 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.417 ' N ' HD22 ' A' ' 415' ' ' LEU . 3.9 mm? -105.48 119.74 39.87 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 178.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 416' ' ' ASP . . . . . 0.403 ' CB ' HD11 ' A' ' 420' ' ' ILE . 0.1 OUTLIER -82.98 -170.56 3.09 Favored 'General case' 0 N--CA 1.514 2.77 0 O-C-N 122.004 -0.435 . . . . 0.0 111.416 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -49.44 123.01 6.86 Favored 'General case' 0 N--CA 1.516 2.839 0 CA-C-O 121.202 0.525 . . . . 0.0 110.866 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 95.03 -0.24 64.16 Favored Glycine 0 N--CA 1.507 3.382 0 CA-C-O 118.909 -0.939 . . . . 0.0 111.794 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 419' ' ' PHE . . . . . 0.412 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 20.6 t80 66.44 71.44 0.4 Allowed 'General case' 0 N--CA 1.506 2.352 0 CA-C-N 119.306 1.553 . . . . 0.0 109.34 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.578 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.15 151.0 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.479 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.3 m -63.74 104.1 0.63 Allowed 'General case' 0 N--CA 1.511 2.607 0 CA-C-O 121.532 0.682 . . . . 0.0 112.681 -176.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 3.5 m -89.19 155.41 19.43 Favored 'General case' 0 N--CA 1.516 2.861 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.57 -171.57 0.28 Allowed 'General case' 0 N--CA 1.506 2.347 0 CA-C-O 121.455 0.645 . . . . 0.0 111.457 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.516 HG23 ' N ' ' A' ' 425' ' ' ASP . 3.6 tt -115.84 -139.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.283 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 425' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 424' ' ' ILE . 17.3 m-20 64.16 83.0 0.17 Allowed 'General case' 0 N--CA 1.512 2.649 0 CA-C-N 120.064 1.302 . . . . 0.0 110.131 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.522 3.143 0 C-N-CA 123.722 0.809 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 22.3 m . . . . . 0 CA--C 1.556 1.199 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.92 -174.57 2.23 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 122.866 2.378 . . . . 0.0 112.764 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.99 132.44 9.34 Favored 'General case' 0 N--CA 1.52 3.052 0 C-N-CA 122.756 0.422 . . . . 0.0 111.492 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -49.59 2.13 Favored Glycine 0 N--CA 1.505 3.236 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -178.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 37.4 m-85 -77.41 85.68 3.81 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.27 -172.86 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.521 3.081 0 O-C-N 121.778 -0.576 . . . . 0.0 110.805 -178.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.417 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.9 OUTLIER -104.13 121.18 42.7 Favored 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.28 -174.41 5.21 Favored 'General case' 0 N--CA 1.512 2.657 0 O-C-N 121.956 -0.465 . . . . 0.0 111.1 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -54.01 116.43 2.56 Favored 'General case' 0 N--CA 1.513 2.717 0 CA-C-O 121.215 0.531 . . . . 0.0 110.124 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.57 -3.93 30.92 Favored Glycine 0 N--CA 1.507 3.368 0 CA-C-O 118.773 -1.015 . . . . 0.0 111.776 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 21.0 t80 68.26 69.21 0.32 Allowed 'General case' 0 N--CA 1.505 2.286 0 CA-C-N 119.49 1.645 . . . . 0.0 109.916 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.599 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -139.09 151.99 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.501 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.8 t -71.11 114.17 8.9 Favored 'General case' 0 N--CA 1.512 2.652 0 O-C-N 121.613 -0.679 . . . . 0.0 110.689 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.17 -173.92 3.07 Favored 'General case' 0 N--CA 1.516 2.863 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.24 -172.2 0.87 Allowed 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.623 -0.673 . . . . 0.0 111.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.454 HG12 ' HB2' ' A' ' 426' ' ' GLU . 0.4 OUTLIER -84.91 -41.25 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.766 -0.583 . . . . 0.0 110.015 -179.903 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 53.59 47.19 24.46 Favored 'General case' 0 N--CA 1.511 2.623 0 CA-C-O 121.531 0.681 . . . . 0.0 111.027 178.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 426' ' ' GLU . . . . . 0.454 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.871 -0.518 . . . . 0.0 110.113 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 CA--C 1.557 1.232 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -76.92 -170.7 0.96 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 123.009 2.472 . . . . 0.0 112.605 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -47.2 130.21 12.8 Favored 'General case' 0 N--CA 1.521 3.086 0 CA-C-O 120.878 0.37 . . . . 0.0 111.063 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 412' ' ' GLY . . . . . 0.459 ' HA3' HG13 ' A' ' 424' ' ' ILE . . . 95.27 -48.73 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -78.71 86.65 4.65 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 415' ' ' LEU . 8.4 pt -89.7 -170.93 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.166 0 O-C-N 121.565 -0.71 . . . . 0.0 111.523 -178.16 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.514 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -111.86 120.57 42.41 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.45 -173.94 2.52 Favored 'General case' 0 N--CA 1.514 2.742 0 O-C-N 122.12 -0.362 . . . . 0.0 111.341 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 49.63 -94.79 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.777 0 C-N-CA 123.527 0.731 . . . . 0.0 111.075 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -129.39 50.72 0.88 Allowed Glycine 0 N--CA 1.503 3.15 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 178.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 419' ' ' PHE . . . . . 0.514 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 16.6 t80 72.42 69.5 0.14 Allowed 'General case' 0 N--CA 1.506 2.364 0 CA-C-O 121.84 0.829 . . . . 0.0 109.768 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.79 153.77 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.687 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -63.92 104.32 0.69 Allowed 'General case' 0 N--CA 1.511 2.61 0 CA-C-O 121.578 0.704 . . . . 0.0 111.76 -177.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.77 167.88 12.93 Favored 'General case' 0 N--CA 1.517 2.905 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -68.67 -172.92 0.4 Allowed 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.538 -0.726 . . . . 0.0 111.131 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.48 HG12 ' HB2' ' A' ' 426' ' ' GLU . 2.6 tt -105.8 -54.19 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.68 0 O-C-N 121.66 -0.65 . . . . 0.0 110.929 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 53.31 48.36 22.2 Favored 'General case' 0 N--CA 1.512 2.659 0 CA-C-O 121.458 0.647 . . . . 0.0 111.168 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 426' ' ' GLU . . . . . 0.48 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.512 2.629 0 O-C-N 121.81 -0.556 . . . . 0.0 109.969 179.239 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 409' ' ' CYS . . . . . 0.412 ' SG ' HD21 ' A' ' 415' ' ' LEU . 2.6 m . . . . . 0 CA--C 1.552 1.048 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 410' ' ' PRO . . . . . 0.441 ' HG2' ' CD2' ' A' ' 413' ' ' TYR . 33.9 Cg_endo -76.44 170.26 20.31 Favored 'Trans proline' 0 CA--C 1.553 1.457 0 C-N-CA 122.695 2.263 . . . . 0.0 112.385 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -49.19 132.36 19.58 Favored 'General case' 0 N--CA 1.518 2.928 0 CA-C-O 121.05 0.452 . . . . 0.0 111.55 -179.229 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.1 -43.49 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -178.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 413' ' ' TYR . . . . . 0.441 ' CD2' ' HG2' ' A' ' 410' ' ' PRO . 97.2 m-85 -76.15 83.95 2.98 Favored 'General case' 0 N--CA 1.503 2.191 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.32 153.97 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.135 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.672 -178.459 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.412 HD21 ' SG ' ' A' ' 409' ' ' CYS . 0.5 OUTLIER -96.28 116.82 29.62 Favored 'General case' 0 N--CA 1.505 2.323 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.491 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -170.73 2.81 Favored 'General case' 0 N--CA 1.513 2.706 0 O-C-N 121.824 -0.547 . . . . 0.0 111.027 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -50.95 127.95 20.07 Favored 'General case' 0 N--CA 1.511 2.598 0 CA-C-O 121.353 0.597 . . . . 0.0 110.75 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 92.75 -0.37 70.08 Favored Glycine 0 N--CA 1.505 3.242 0 CA-C-O 118.57 -1.128 . . . . 0.0 112.187 -179.027 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 33.6 t80 66.89 70.07 0.39 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-N 119.785 1.792 . . . . 0.0 109.196 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.562 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -134.4 152.33 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.543 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 56.9 m -70.05 97.99 1.24 Allowed 'General case' 0 N--CA 1.508 2.452 0 N-CA-C 112.523 0.564 . . . . 0.0 112.523 -177.269 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.22 -170.62 3.13 Favored 'General case' 0 N--CA 1.516 2.858 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -72.86 -178.63 2.82 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.075 -1.015 . . . . 0.0 111.354 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.474 HG12 ' HB2' ' A' ' 426' ' ' GLU . 5.8 tt -109.78 -52.85 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.682 0 O-C-N 121.924 -0.485 . . . . 0.0 110.867 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 58.32 63.03 1.83 Allowed 'General case' 0 N--CA 1.511 2.603 0 CA-C-O 121.687 0.756 . . . . 0.0 110.511 179.296 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 426' ' ' GLU . . . . . 0.474 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.511 2.613 0 O-C-N 122.028 -0.42 . . . . 0.0 110.169 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 11.9 m . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 410' ' ' PRO . . . . . 0.421 ' HG2' ' CD1' ' A' ' 413' ' ' TYR . 33.4 Cg_endo -76.31 -179.29 5.13 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.84 2.36 . . . . 0.0 112.879 -179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -50.25 132.07 24.06 Favored 'General case' 0 N--CA 1.519 3.018 0 CA-C-O 121.002 0.43 . . . . 0.0 111.395 -179.257 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.05 -45.25 1.81 Allowed Glycine 0 N--CA 1.508 3.48 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -178.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 413' ' ' TYR . . . . . 0.421 ' CD1' ' HG2' ' A' ' 410' ' ' PRO . 13.9 m-85 -83.06 88.27 6.88 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.456 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -101.2 -172.59 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.316 0 O-C-N 121.584 -0.698 . . . . 0.0 111.311 -177.83 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.435 HD12 ' C ' ' A' ' 419' ' ' PHE . 3.4 mm? -95.73 126.64 41.14 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -75.35 -173.6 2.12 Favored 'General case' 0 N--CA 1.515 2.775 0 O-C-N 121.979 -0.451 . . . . 0.0 110.758 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -53.97 -34.04 58.64 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 121.678 -0.639 . . . . 0.0 111.125 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -88.95 10.39 72.95 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 118.808 -0.995 . . . . 0.0 112.542 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 419' ' ' PHE . . . . . 0.435 ' C ' HD12 ' A' ' 415' ' ' LEU . 12.2 t80 61.05 60.64 1.77 Allowed 'General case' 0 N--CA 1.508 2.466 0 CA-C-N 119.726 1.763 . . . . 0.0 110.038 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.533 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -138.35 159.32 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.667 0 O-C-N 121.779 -0.575 . . . . 0.0 109.636 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.1 t -64.65 103.96 0.75 Allowed 'General case' 0 N--CA 1.512 2.628 0 CA-C-O 121.48 0.657 . . . . 0.0 111.13 -178.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 422' ' ' THR . . . . . 0.456 ' HB ' HD13 ' A' ' 414' ' ' ILE . 5.8 m -86.21 166.12 15.97 Favored 'General case' 0 N--CA 1.514 2.756 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.081 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -65.76 -172.52 0.13 Allowed 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 121.345 0.593 . . . . 0.0 110.795 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -78.57 -33.08 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.653 0 O-C-N 121.538 -0.726 . . . . 0.0 110.13 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 54.74 46.72 24.03 Favored 'General case' 0 N--CA 1.514 2.729 0 CA-C-O 121.656 0.741 . . . . 0.0 110.25 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 . . . . . 0 N--CA 1.507 2.424 0 O-C-N 122.042 -0.412 . . . . 0.0 110.231 -179.811 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.552 1.042 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -76.92 -176.41 3.16 Favored 'Trans proline' 0 CA--C 1.556 1.585 0 C-N-CA 122.627 2.218 . . . . 0.0 112.214 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -51.49 131.82 29.44 Favored 'General case' 0 N--CA 1.517 2.883 0 CA-C-O 121.003 0.43 . . . . 0.0 111.251 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.35 -40.16 2.56 Favored Glycine 0 N--CA 1.507 3.394 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 413' ' ' TYR . . . . . 0.535 ' HA ' HD11 ' A' ' 424' ' ' ILE . 82.0 m-85 -83.47 84.99 7.32 Favored 'General case' 0 N--CA 1.5 2.037 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 6.1 pt -83.01 173.42 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.519 3.007 0 CA-C-O 121.463 0.649 . . . . 0.0 111.749 -178.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.458 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -100.85 154.05 18.97 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-O 121.209 0.528 . . . . 0.0 109.888 179.055 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.7 -168.14 3.02 Favored 'General case' 0 N--CA 1.51 2.572 0 O-C-N 122.085 -0.384 . . . . 0.0 110.864 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 54.94 -90.79 0.03 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.319 0.648 . . . . 0.0 110.66 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -131.57 46.27 1.08 Allowed Glycine 0 N--CA 1.503 3.104 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 28.8 t80 70.65 67.3 0.19 Allowed 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 122.135 0.969 . . . . 0.0 109.254 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -138.96 156.18 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.719 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.971 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 421' ' ' CYS . . . . . 0.458 ' HA ' HD22 ' A' ' 415' ' ' LEU . 1.6 t -62.04 118.48 7.36 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 122.086 -0.384 . . . . 0.0 110.752 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 85.9 m -109.3 139.31 44.41 Favored 'General case' 0 N--CA 1.508 2.472 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -74.89 -174.78 2.31 Favored 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.478 0.656 . . . . 0.0 111.346 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.535 HD11 ' HA ' ' A' ' 413' ' ' TYR . 2.2 mm -121.38 -147.46 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.371 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -115.81 39.4 3.04 Favored 'General case' 0 N--CA 1.505 2.324 0 O-C-N 121.296 -0.877 . . . . 0.0 108.983 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 . . . . . 0 N--CA 1.508 2.453 0 O-C-N 122.019 -0.426 . . . . 0.0 110.076 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.557 1.248 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -77.14 -167.8 0.51 Allowed 'Trans proline' 0 N--CA 1.5 1.908 0 C-N-CA 123.247 2.631 . . . . 0.0 112.471 -179.098 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -47.54 131.0 14.19 Favored 'General case' 0 N--CA 1.521 3.081 0 CA-C-O 121.002 0.429 . . . . 0.0 111.125 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 412' ' ' GLY . . . . . 0.581 ' HA3' HD12 ' A' ' 424' ' ' ILE . . . 96.47 -48.53 1.69 Allowed Glycine 0 N--CA 1.509 3.546 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -82.88 86.49 6.93 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.98 -168.51 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.366 0 O-C-N 121.498 -0.751 . . . . 0.0 112.691 -176.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.458 ' N ' HD22 ' A' ' 415' ' ' LEU . 3.9 mm? -106.1 141.13 37.98 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -133.8 -175.51 3.86 Favored 'General case' 0 N--CA 1.516 2.871 0 O-C-N 121.873 -0.517 . . . . 0.0 111.469 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 51.19 -96.65 0.05 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.352 0.661 . . . . 0.0 110.905 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -124.57 48.2 0.97 Allowed Glycine 0 N--CA 1.502 3.083 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 419' ' ' PHE . . . . . 0.434 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 17.8 t80 70.84 70.9 0.19 Allowed 'General case' 0 N--CA 1.505 2.306 0 CA-C-O 121.917 0.865 . . . . 0.0 109.801 -179.271 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.558 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -132.88 151.35 34.18 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.621 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.88 116.81 4.02 Favored 'General case' 0 N--CA 1.514 2.766 0 CA-C-O 121.402 0.62 . . . . 0.0 111.904 -177.49 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 31.0 m -123.41 152.05 41.99 Favored 'General case' 0 N--CA 1.51 2.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.27 -162.56 0.3 Allowed 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.454 0.645 . . . . 0.0 111.252 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 424' ' ' ILE . . . . . 0.581 HD12 ' HA3' ' A' ' 412' ' ' GLY . 1.1 tt -81.42 -35.74 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.928 -0.483 . . . . 0.0 110.294 -179.161 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 53.86 55.98 7.73 Favored 'General case' 0 N--CA 1.51 2.562 0 CA-C-O 121.421 0.629 . . . . 0.0 110.146 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 N--CA 1.521 3.099 0 C-N-CA 123.879 0.872 . . . . 0.0 110.423 -179.537 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 10.8 m . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -76.95 -171.07 1.04 Allowed 'Trans proline' 0 N--CA 1.499 1.829 0 C-N-CA 123.003 2.469 . . . . 0.0 112.765 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.3 131.15 8.17 Favored 'General case' 0 N--CA 1.521 3.084 0 C-N-CA 122.806 0.442 . . . . 0.0 111.479 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -50.87 2.12 Favored Glycine 0 N--CA 1.504 3.208 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -177.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -78.49 87.34 4.48 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 414' ' ' ILE . . . . . 0.489 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -102.8 -170.67 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.153 0 O-C-N 121.53 -0.731 . . . . 0.0 110.984 -178.602 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 415' ' ' LEU . . . . . 0.523 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -100.55 123.1 44.3 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.94 -169.45 0.91 Allowed 'General case' 0 N--CA 1.517 2.883 0 O-C-N 121.923 -0.486 . . . . 0.0 111.097 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -51.98 -37.75 54.2 Favored 'General case' 0 N--CA 1.519 3.01 0 O-C-N 121.728 -0.608 . . . . 0.0 111.878 -179.164 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -91.05 14.18 64.19 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 119.002 -0.888 . . . . 0.0 112.209 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 419' ' ' PHE . . . . . 0.523 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 10.8 t80 58.3 62.55 1.97 Allowed 'General case' 0 N--CA 1.506 2.33 0 CA-C-N 119.347 1.574 . . . . 0.0 110.08 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 420' ' ' ILE . . . . . 0.524 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.65 159.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.511 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.686 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.3 t -65.7 102.84 0.79 Allowed 'General case' 0 N--CA 1.511 2.604 0 CA-C-O 121.464 0.65 . . . . 0.0 111.167 -178.467 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 422' ' ' THR . . . . . 0.489 ' HB ' HD13 ' A' ' 414' ' ' ILE . 7.8 m -84.53 168.41 15.44 Favored 'General case' 0 N--CA 1.514 2.75 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 423' ' ' ASP . . . . . 0.4 ' N ' HG22 ' A' ' 422' ' ' THR . 10.5 m-20 -64.81 -171.75 0.07 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 121.585 -0.697 . . . . 0.0 110.589 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -81.98 -41.82 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.597 0 O-C-N 121.324 -0.86 . . . . 0.0 109.823 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 51.97 46.02 27.29 Favored 'General case' 0 N--CA 1.512 2.665 0 CA-C-O 121.525 0.678 . . . . 0.0 111.064 178.693 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.91 -0.494 . . . . 0.0 110.032 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 409' ' ' CYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 15.3 m . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -77.77 -172.9 1.61 Allowed 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.956 2.437 . . . . 0.0 112.731 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.26 134.23 23.02 Favored 'General case' 0 N--CA 1.518 2.961 0 CA-C-O 121.031 0.443 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.38 -43.87 2.05 Favored Glycine 0 N--CA 1.509 3.517 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 413' ' ' TYR . . . . . 0.466 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 51.3 m-85 -84.89 87.44 7.34 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.81 -176.32 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.14 0 O-C-N 121.582 -0.699 . . . . 0.0 111.715 -177.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.599 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.1 mm? -103.1 116.87 33.34 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.5 -172.17 2.5 Favored 'General case' 0 N--CA 1.512 2.636 0 O-C-N 122.097 -0.377 . . . . 0.0 110.766 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 56.8 -87.25 0.02 OUTLIER 'General case' 0 N--CA 1.513 2.701 0 C-N-CA 123.233 0.613 . . . . 0.0 110.289 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -133.38 44.58 1.18 Allowed Glycine 0 N--CA 1.502 3.078 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 178.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 419' ' ' PHE . . . . . 0.599 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 18.6 t80 70.51 64.97 0.2 Allowed 'General case' 0 N--CA 1.505 2.315 0 CA-C-O 121.992 0.901 . . . . 0.0 109.491 -179.15 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.591 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -135.28 152.53 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.713 0 O-C-N 121.865 -0.522 . . . . 0.0 109.858 179.279 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.1 m -62.02 109.2 1.21 Allowed 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 121.242 0.544 . . . . 0.0 110.108 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.4 m -91.0 149.27 21.91 Favored 'General case' 0 N--CA 1.512 2.651 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.342 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -74.67 -173.35 1.79 Allowed 'General case' 0 N--CA 1.503 2.221 0 CA-C-O 121.231 0.538 . . . . 0.0 110.992 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.659 HG12 ' OXT' ' A' ' 426' ' ' GLU . 11.8 tt -174.78 -50.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.886 0 O-C-N 121.884 -0.51 . . . . 0.0 110.99 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 425' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 424' ' ' ILE . 8.9 m-20 61.93 58.26 1.95 Allowed 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 426' ' ' GLU . . . . . 0.659 ' OXT' HG12 ' A' ' 424' ' ' ILE . 1.1 mp0 . . . . . 0 N--CA 1.521 3.081 0 C-N-CA 123.962 0.905 . . . . 0.0 110.658 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.556 1.189 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.53 179.05 6.8 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.857 2.371 . . . . 0.0 112.866 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -46.73 133.91 10.21 Favored 'General case' 0 N--CA 1.521 3.083 0 CA-C-O 121.106 0.479 . . . . 0.0 111.271 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 95.38 -49.28 1.89 Allowed Glycine 0 N--CA 1.507 3.397 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 -177.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -81.14 88.42 6.0 Favored 'General case' 0 N--CA 1.499 2.006 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 178.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.47 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -95.39 -176.35 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.28 0 O-C-N 121.522 -0.737 . . . . 0.0 110.417 -178.857 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.2 OUTLIER -104.98 139.01 40.31 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.591 -0.693 . . . . 0.0 109.414 179.704 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.51 -173.54 2.5 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -54.07 119.25 4.82 Favored 'General case' 0 N--CA 1.515 2.799 0 CA-C-O 121.113 0.482 . . . . 0.0 110.399 -179.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.13 -4.44 31.7 Favored Glycine 0 N--CA 1.506 3.34 0 CA-C-O 118.775 -1.014 . . . . 0.0 111.862 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 22.7 t80 68.15 66.86 0.34 Allowed 'General case' 0 N--CA 1.508 2.428 0 CA-C-N 119.505 1.652 . . . . 0.0 109.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.79 152.83 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.575 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.7 t -70.93 115.75 10.43 Favored 'General case' 0 N--CA 1.511 2.614 0 CA-C-O 121.398 0.618 . . . . 0.0 111.764 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 422' ' ' THR . . . . . 0.47 ' HB ' HD13 ' A' ' 414' ' ' ILE . 1.7 m -96.63 162.9 13.25 Favored 'General case' 0 N--CA 1.513 2.685 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -63.32 -173.8 0.07 Allowed 'General case' 0 N--CA 1.504 2.264 0 CA-C-O 121.644 0.735 . . . . 0.0 110.971 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -79.63 -34.63 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 121.509 -0.744 . . . . 0.0 109.876 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 57.71 52.32 8.34 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-O 121.771 0.796 . . . . 0.0 110.168 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.507 2.386 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.878 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 CA--C 1.556 1.2 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -75.68 -168.97 0.59 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.982 2.455 . . . . 0.0 112.477 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -47.11 130.4 12.59 Favored 'General case' 0 N--CA 1.519 2.99 0 CA-C-O 121.031 0.443 . . . . 0.0 111.183 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 412' ' ' GLY . . . . . 0.523 ' CA ' HD12 ' A' ' 424' ' ' ILE . . . 97.71 -49.05 1.46 Allowed Glycine 0 N--CA 1.508 3.475 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -80.7 88.57 5.76 Favored 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.469 HD13 ' C ' ' A' ' 414' ' ' ILE . 0.0 OUTLIER -86.95 -172.97 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.338 0 CA-C-O 121.352 0.596 . . . . 0.0 112.474 -176.784 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.595 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -104.44 153.96 20.46 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.853 -0.53 . . . . 0.0 109.925 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 416' ' ' ASP . . . . . 0.445 ' HB2' ' OG1' ' A' ' 422' ' ' THR . 0.4 OUTLIER -106.25 -171.54 1.92 Allowed 'General case' 0 N--CA 1.514 2.766 0 O-C-N 121.937 -0.477 . . . . 0.0 111.003 179.623 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -51.29 130.17 26.24 Favored 'General case' 0 N--CA 1.515 2.789 0 CA-C-O 121.16 0.505 . . . . 0.0 110.855 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 96.81 -6.12 64.43 Favored Glycine 0 N--CA 1.507 3.409 0 CA-C-O 119.036 -0.869 . . . . 0.0 111.453 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 25.9 t80 68.43 71.41 0.3 Allowed 'General case' 0 N--CA 1.509 2.479 0 CA-C-N 119.092 1.446 . . . . 0.0 109.229 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.509 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.0 pp -137.6 153.94 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.497 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.718 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 421' ' ' CYS . . . . . 0.595 ' HA ' HD22 ' A' ' 415' ' ' LEU . 0.1 OUTLIER -60.0 124.98 21.9 Favored 'General case' 0 N--CA 1.516 2.848 0 CA-C-O 121.013 0.435 . . . . 0.0 111.382 -178.623 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 422' ' ' THR . . . . . 0.445 ' OG1' ' HB2' ' A' ' 416' ' ' ASP . 6.5 m -134.3 150.03 50.94 Favored 'General case' 0 N--CA 1.509 2.506 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -91.82 143.61 26.34 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 122.405 1.098 . . . . 0.0 111.04 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.523 HD12 ' CA ' ' A' ' 412' ' ' GLY . 20.9 tt -55.04 -37.06 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.921 178.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 55.25 53.43 10.05 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-O 121.692 0.758 . . . . 0.0 110.416 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.478 0 O-C-N 121.931 -0.481 . . . . 0.0 110.045 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 409' ' ' CYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 1.2 m . . . . . 0 CA--C 1.558 1.288 0 N-CA-C 110.61 -0.144 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -76.17 177.84 8.25 Favored 'Trans proline' 0 N--CA 1.496 1.676 0 C-N-CA 123.007 2.471 . . . . 0.0 113.282 -178.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.82 134.02 25.75 Favored 'General case' 0 N--CA 1.518 2.959 0 CA-C-O 121.032 0.444 . . . . 0.0 111.194 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.49 -43.81 2.31 Favored Glycine 0 N--CA 1.508 3.484 0 N-CA-C 108.761 -1.735 . . . . 0.0 108.761 -177.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 413' ' ' TYR . . . . . 0.522 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 74.6 m-85 -85.74 75.77 10.03 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 2.1 pt -67.08 172.69 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.527 3.413 0 O-C-N 121.568 -0.708 . . . . 0.0 112.32 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.417 ' N ' HD22 ' A' ' 415' ' ' LEU . 3.9 mm? -105.48 119.74 39.87 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 178.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 416' ' ' ASP . . . . . 0.403 ' CB ' HD11 ' A' ' 420' ' ' ILE . 0.1 OUTLIER -82.98 -170.56 3.09 Favored 'General case' 0 N--CA 1.514 2.77 0 O-C-N 122.004 -0.435 . . . . 0.0 111.416 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -49.44 123.01 6.86 Favored 'General case' 0 N--CA 1.516 2.839 0 CA-C-O 121.202 0.525 . . . . 0.0 110.866 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 95.03 -0.24 64.16 Favored Glycine 0 N--CA 1.507 3.382 0 CA-C-O 118.909 -0.939 . . . . 0.0 111.794 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 419' ' ' PHE . . . . . 0.412 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 20.6 t80 66.44 71.44 0.4 Allowed 'General case' 0 N--CA 1.506 2.352 0 CA-C-N 119.306 1.553 . . . . 0.0 109.34 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.578 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.15 151.0 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.479 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.3 m -63.74 104.1 0.63 Allowed 'General case' 0 N--CA 1.511 2.607 0 CA-C-O 121.532 0.682 . . . . 0.0 112.681 -176.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 3.5 m -89.19 155.41 19.43 Favored 'General case' 0 N--CA 1.516 2.861 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.57 -171.57 0.28 Allowed 'General case' 0 N--CA 1.506 2.347 0 CA-C-O 121.455 0.645 . . . . 0.0 111.457 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.516 HG23 ' N ' ' A' ' 425' ' ' ASP . 3.6 tt -115.84 -139.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.283 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 425' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 424' ' ' ILE . 17.3 m-20 64.16 83.0 0.17 Allowed 'General case' 0 N--CA 1.512 2.649 0 CA-C-N 120.064 1.302 . . . . 0.0 110.131 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.522 3.143 0 C-N-CA 123.722 0.809 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 22.3 m . . . . . 0 CA--C 1.556 1.199 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.92 -174.57 2.23 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 122.866 2.378 . . . . 0.0 112.764 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.99 132.44 9.34 Favored 'General case' 0 N--CA 1.52 3.052 0 C-N-CA 122.756 0.422 . . . . 0.0 111.492 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -49.59 2.13 Favored Glycine 0 N--CA 1.505 3.236 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -178.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 37.4 m-85 -77.41 85.68 3.81 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.27 -172.86 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.521 3.081 0 O-C-N 121.778 -0.576 . . . . 0.0 110.805 -178.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.417 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.9 OUTLIER -104.13 121.18 42.7 Favored 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.28 -174.41 5.21 Favored 'General case' 0 N--CA 1.512 2.657 0 O-C-N 121.956 -0.465 . . . . 0.0 111.1 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -54.01 116.43 2.56 Favored 'General case' 0 N--CA 1.513 2.717 0 CA-C-O 121.215 0.531 . . . . 0.0 110.124 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.57 -3.93 30.92 Favored Glycine 0 N--CA 1.507 3.368 0 CA-C-O 118.773 -1.015 . . . . 0.0 111.776 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 21.0 t80 68.26 69.21 0.32 Allowed 'General case' 0 N--CA 1.505 2.286 0 CA-C-N 119.49 1.645 . . . . 0.0 109.916 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.599 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -139.09 151.99 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.501 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.8 t -71.11 114.17 8.9 Favored 'General case' 0 N--CA 1.512 2.652 0 O-C-N 121.613 -0.679 . . . . 0.0 110.689 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.17 -173.92 3.07 Favored 'General case' 0 N--CA 1.516 2.863 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.24 -172.2 0.87 Allowed 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.623 -0.673 . . . . 0.0 111.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.454 HG12 ' HB2' ' A' ' 426' ' ' GLU . 0.4 OUTLIER -84.91 -41.25 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.766 -0.583 . . . . 0.0 110.015 -179.903 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 53.59 47.19 24.46 Favored 'General case' 0 N--CA 1.511 2.623 0 CA-C-O 121.531 0.681 . . . . 0.0 111.027 178.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 426' ' ' GLU . . . . . 0.454 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.871 -0.518 . . . . 0.0 110.113 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 CA--C 1.557 1.232 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -76.92 -170.7 0.96 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 123.009 2.472 . . . . 0.0 112.605 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -47.2 130.21 12.8 Favored 'General case' 0 N--CA 1.521 3.086 0 CA-C-O 120.878 0.37 . . . . 0.0 111.063 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 412' ' ' GLY . . . . . 0.459 ' HA3' HG13 ' A' ' 424' ' ' ILE . . . 95.27 -48.73 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -78.71 86.65 4.65 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 415' ' ' LEU . 8.4 pt -89.7 -170.93 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.166 0 O-C-N 121.565 -0.71 . . . . 0.0 111.523 -178.16 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.514 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -111.86 120.57 42.41 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.45 -173.94 2.52 Favored 'General case' 0 N--CA 1.514 2.742 0 O-C-N 122.12 -0.362 . . . . 0.0 111.341 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 49.63 -94.79 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.777 0 C-N-CA 123.527 0.731 . . . . 0.0 111.075 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -129.39 50.72 0.88 Allowed Glycine 0 N--CA 1.503 3.15 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 178.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 419' ' ' PHE . . . . . 0.514 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 16.6 t80 72.42 69.5 0.14 Allowed 'General case' 0 N--CA 1.506 2.364 0 CA-C-O 121.84 0.829 . . . . 0.0 109.768 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.79 153.77 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.687 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -63.92 104.32 0.69 Allowed 'General case' 0 N--CA 1.511 2.61 0 CA-C-O 121.578 0.704 . . . . 0.0 111.76 -177.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.77 167.88 12.93 Favored 'General case' 0 N--CA 1.517 2.905 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -68.67 -172.92 0.4 Allowed 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.538 -0.726 . . . . 0.0 111.131 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.48 HG12 ' HB2' ' A' ' 426' ' ' GLU . 2.6 tt -105.8 -54.19 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.68 0 O-C-N 121.66 -0.65 . . . . 0.0 110.929 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 53.31 48.36 22.2 Favored 'General case' 0 N--CA 1.512 2.659 0 CA-C-O 121.458 0.647 . . . . 0.0 111.168 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 426' ' ' GLU . . . . . 0.48 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.512 2.629 0 O-C-N 121.81 -0.556 . . . . 0.0 109.969 179.239 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 409' ' ' CYS . . . . . 0.412 ' SG ' HD21 ' A' ' 415' ' ' LEU . 2.6 m . . . . . 0 CA--C 1.552 1.048 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 410' ' ' PRO . . . . . 0.441 ' HG2' ' CD2' ' A' ' 413' ' ' TYR . 33.9 Cg_endo -76.44 170.26 20.31 Favored 'Trans proline' 0 CA--C 1.553 1.457 0 C-N-CA 122.695 2.263 . . . . 0.0 112.385 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -49.19 132.36 19.58 Favored 'General case' 0 N--CA 1.518 2.928 0 CA-C-O 121.05 0.452 . . . . 0.0 111.55 -179.229 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.1 -43.49 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -178.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 413' ' ' TYR . . . . . 0.441 ' CD2' ' HG2' ' A' ' 410' ' ' PRO . 97.2 m-85 -76.15 83.95 2.98 Favored 'General case' 0 N--CA 1.503 2.191 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.32 153.97 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.135 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.672 -178.459 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.412 HD21 ' SG ' ' A' ' 409' ' ' CYS . 0.5 OUTLIER -96.28 116.82 29.62 Favored 'General case' 0 N--CA 1.505 2.323 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.491 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -170.73 2.81 Favored 'General case' 0 N--CA 1.513 2.706 0 O-C-N 121.824 -0.547 . . . . 0.0 111.027 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -50.95 127.95 20.07 Favored 'General case' 0 N--CA 1.511 2.598 0 CA-C-O 121.353 0.597 . . . . 0.0 110.75 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 92.75 -0.37 70.08 Favored Glycine 0 N--CA 1.505 3.242 0 CA-C-O 118.57 -1.128 . . . . 0.0 112.187 -179.027 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 33.6 t80 66.89 70.07 0.39 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-N 119.785 1.792 . . . . 0.0 109.196 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.562 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -134.4 152.33 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.543 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 56.9 m -70.05 97.99 1.24 Allowed 'General case' 0 N--CA 1.508 2.452 0 N-CA-C 112.523 0.564 . . . . 0.0 112.523 -177.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.22 -170.62 3.13 Favored 'General case' 0 N--CA 1.516 2.858 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -72.86 -178.63 2.82 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.075 -1.015 . . . . 0.0 111.354 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.474 HG12 ' HB2' ' A' ' 426' ' ' GLU . 5.8 tt -109.78 -52.85 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.682 0 O-C-N 121.924 -0.485 . . . . 0.0 110.867 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 58.32 63.03 1.83 Allowed 'General case' 0 N--CA 1.511 2.603 0 CA-C-O 121.687 0.756 . . . . 0.0 110.511 179.296 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 426' ' ' GLU . . . . . 0.474 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.511 2.613 0 O-C-N 122.028 -0.42 . . . . 0.0 110.169 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 11.9 m . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 410' ' ' PRO . . . . . 0.421 ' HG2' ' CD1' ' A' ' 413' ' ' TYR . 33.4 Cg_endo -76.31 -179.29 5.13 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.84 2.36 . . . . 0.0 112.879 -179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -50.25 132.07 24.06 Favored 'General case' 0 N--CA 1.519 3.018 0 CA-C-O 121.002 0.43 . . . . 0.0 111.395 -179.257 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.05 -45.25 1.81 Allowed Glycine 0 N--CA 1.508 3.48 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -178.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 413' ' ' TYR . . . . . 0.421 ' CD1' ' HG2' ' A' ' 410' ' ' PRO . 13.9 m-85 -83.06 88.27 6.88 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.456 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -101.2 -172.59 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.316 0 O-C-N 121.584 -0.698 . . . . 0.0 111.311 -177.83 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.435 HD12 ' C ' ' A' ' 419' ' ' PHE . 3.4 mm? -95.73 126.64 41.14 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -75.35 -173.6 2.12 Favored 'General case' 0 N--CA 1.515 2.775 0 O-C-N 121.979 -0.451 . . . . 0.0 110.758 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -53.97 -34.04 58.64 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 121.678 -0.639 . . . . 0.0 111.125 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -88.95 10.39 72.95 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 118.808 -0.995 . . . . 0.0 112.542 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 419' ' ' PHE . . . . . 0.435 ' C ' HD12 ' A' ' 415' ' ' LEU . 12.2 t80 61.05 60.64 1.77 Allowed 'General case' 0 N--CA 1.508 2.466 0 CA-C-N 119.726 1.763 . . . . 0.0 110.038 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.533 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -138.35 159.32 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.667 0 O-C-N 121.779 -0.575 . . . . 0.0 109.636 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.1 t -64.65 103.96 0.75 Allowed 'General case' 0 N--CA 1.512 2.628 0 CA-C-O 121.48 0.657 . . . . 0.0 111.13 -178.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 422' ' ' THR . . . . . 0.456 ' HB ' HD13 ' A' ' 414' ' ' ILE . 5.8 m -86.21 166.12 15.97 Favored 'General case' 0 N--CA 1.514 2.756 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.081 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -65.76 -172.52 0.13 Allowed 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 121.345 0.593 . . . . 0.0 110.795 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -78.57 -33.08 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.653 0 O-C-N 121.538 -0.726 . . . . 0.0 110.13 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 54.74 46.72 24.03 Favored 'General case' 0 N--CA 1.514 2.729 0 CA-C-O 121.656 0.741 . . . . 0.0 110.25 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 . . . . . 0 N--CA 1.507 2.424 0 O-C-N 122.042 -0.412 . . . . 0.0 110.231 -179.811 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.552 1.042 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -76.92 -176.41 3.16 Favored 'Trans proline' 0 CA--C 1.556 1.585 0 C-N-CA 122.627 2.218 . . . . 0.0 112.214 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -51.49 131.82 29.44 Favored 'General case' 0 N--CA 1.517 2.883 0 CA-C-O 121.003 0.43 . . . . 0.0 111.251 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.35 -40.16 2.56 Favored Glycine 0 N--CA 1.507 3.394 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 413' ' ' TYR . . . . . 0.535 ' HA ' HD11 ' A' ' 424' ' ' ILE . 82.0 m-85 -83.47 84.99 7.32 Favored 'General case' 0 N--CA 1.5 2.037 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 6.1 pt -83.01 173.42 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.519 3.007 0 CA-C-O 121.463 0.649 . . . . 0.0 111.749 -178.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.458 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -100.85 154.05 18.97 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-O 121.209 0.528 . . . . 0.0 109.888 179.055 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.7 -168.14 3.02 Favored 'General case' 0 N--CA 1.51 2.572 0 O-C-N 122.085 -0.384 . . . . 0.0 110.864 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 54.94 -90.79 0.03 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.319 0.648 . . . . 0.0 110.66 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -131.57 46.27 1.08 Allowed Glycine 0 N--CA 1.503 3.104 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 28.8 t80 70.65 67.3 0.19 Allowed 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 122.135 0.969 . . . . 0.0 109.254 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -138.96 156.18 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.719 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.971 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 421' ' ' CYS . . . . . 0.458 ' HA ' HD22 ' A' ' 415' ' ' LEU . 1.6 t -62.04 118.48 7.36 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 122.086 -0.384 . . . . 0.0 110.752 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 85.9 m -109.3 139.31 44.41 Favored 'General case' 0 N--CA 1.508 2.472 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -74.89 -174.78 2.31 Favored 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.478 0.656 . . . . 0.0 111.346 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.535 HD11 ' HA ' ' A' ' 413' ' ' TYR . 2.2 mm -121.38 -147.46 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.371 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -115.81 39.4 3.04 Favored 'General case' 0 N--CA 1.505 2.324 0 O-C-N 121.296 -0.877 . . . . 0.0 108.983 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 . . . . . 0 N--CA 1.508 2.453 0 O-C-N 122.019 -0.426 . . . . 0.0 110.076 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.557 1.248 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -77.14 -167.8 0.51 Allowed 'Trans proline' 0 N--CA 1.5 1.908 0 C-N-CA 123.247 2.631 . . . . 0.0 112.471 -179.098 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -47.54 131.0 14.19 Favored 'General case' 0 N--CA 1.521 3.081 0 CA-C-O 121.002 0.429 . . . . 0.0 111.125 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 412' ' ' GLY . . . . . 0.581 ' HA3' HD12 ' A' ' 424' ' ' ILE . . . 96.47 -48.53 1.69 Allowed Glycine 0 N--CA 1.509 3.546 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -82.88 86.49 6.93 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.98 -168.51 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.366 0 O-C-N 121.498 -0.751 . . . . 0.0 112.691 -176.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.458 ' N ' HD22 ' A' ' 415' ' ' LEU . 3.9 mm? -106.1 141.13 37.98 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -133.8 -175.51 3.86 Favored 'General case' 0 N--CA 1.516 2.871 0 O-C-N 121.873 -0.517 . . . . 0.0 111.469 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 51.19 -96.65 0.05 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.352 0.661 . . . . 0.0 110.905 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -124.57 48.2 0.97 Allowed Glycine 0 N--CA 1.502 3.083 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 419' ' ' PHE . . . . . 0.434 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 17.8 t80 70.84 70.9 0.19 Allowed 'General case' 0 N--CA 1.505 2.306 0 CA-C-O 121.917 0.865 . . . . 0.0 109.801 -179.271 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.558 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -132.88 151.35 34.18 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.621 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.88 116.81 4.02 Favored 'General case' 0 N--CA 1.514 2.766 0 CA-C-O 121.402 0.62 . . . . 0.0 111.904 -177.49 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 31.0 m -123.41 152.05 41.99 Favored 'General case' 0 N--CA 1.51 2.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.27 -162.56 0.3 Allowed 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.454 0.645 . . . . 0.0 111.252 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 424' ' ' ILE . . . . . 0.581 HD12 ' HA3' ' A' ' 412' ' ' GLY . 1.1 tt -81.42 -35.74 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.928 -0.483 . . . . 0.0 110.294 -179.161 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 53.86 55.98 7.73 Favored 'General case' 0 N--CA 1.51 2.562 0 CA-C-O 121.421 0.629 . . . . 0.0 110.146 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 N--CA 1.521 3.099 0 C-N-CA 123.879 0.872 . . . . 0.0 110.423 -179.537 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 10.8 m . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -76.95 -171.07 1.04 Allowed 'Trans proline' 0 N--CA 1.499 1.829 0 C-N-CA 123.003 2.469 . . . . 0.0 112.765 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.3 131.15 8.17 Favored 'General case' 0 N--CA 1.521 3.084 0 C-N-CA 122.806 0.442 . . . . 0.0 111.479 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -50.87 2.12 Favored Glycine 0 N--CA 1.504 3.208 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -177.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -78.49 87.34 4.48 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 414' ' ' ILE . . . . . 0.489 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -102.8 -170.67 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.153 0 O-C-N 121.53 -0.731 . . . . 0.0 110.984 -178.602 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 415' ' ' LEU . . . . . 0.523 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -100.55 123.1 44.3 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.94 -169.45 0.91 Allowed 'General case' 0 N--CA 1.517 2.883 0 O-C-N 121.923 -0.486 . . . . 0.0 111.097 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -51.98 -37.75 54.2 Favored 'General case' 0 N--CA 1.519 3.01 0 O-C-N 121.728 -0.608 . . . . 0.0 111.878 -179.164 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -91.05 14.18 64.19 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 119.002 -0.888 . . . . 0.0 112.209 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 419' ' ' PHE . . . . . 0.523 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 10.8 t80 58.3 62.55 1.97 Allowed 'General case' 0 N--CA 1.506 2.33 0 CA-C-N 119.347 1.574 . . . . 0.0 110.08 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 420' ' ' ILE . . . . . 0.524 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.65 159.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.511 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.686 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.3 t -65.7 102.84 0.79 Allowed 'General case' 0 N--CA 1.511 2.604 0 CA-C-O 121.464 0.65 . . . . 0.0 111.167 -178.467 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 422' ' ' THR . . . . . 0.489 ' HB ' HD13 ' A' ' 414' ' ' ILE . 7.8 m -84.53 168.41 15.44 Favored 'General case' 0 N--CA 1.514 2.75 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 423' ' ' ASP . . . . . 0.4 ' N ' HG22 ' A' ' 422' ' ' THR . 10.5 m-20 -64.81 -171.75 0.07 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 121.585 -0.697 . . . . 0.0 110.589 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -81.98 -41.82 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.597 0 O-C-N 121.324 -0.86 . . . . 0.0 109.823 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 51.97 46.02 27.29 Favored 'General case' 0 N--CA 1.512 2.665 0 CA-C-O 121.525 0.678 . . . . 0.0 111.064 178.693 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.91 -0.494 . . . . 0.0 110.032 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 15.3 m . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -77.77 -172.9 1.61 Allowed 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.956 2.437 . . . . 0.0 112.731 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.26 134.23 23.02 Favored 'General case' 0 N--CA 1.518 2.961 0 CA-C-O 121.031 0.443 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.38 -43.87 2.05 Favored Glycine 0 N--CA 1.509 3.517 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . 0.466 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 51.3 m-85 -84.89 87.44 7.34 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.81 -176.32 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.14 0 O-C-N 121.582 -0.699 . . . . 0.0 111.715 -177.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.599 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.1 mm? -103.1 116.87 33.34 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.5 -172.17 2.5 Favored 'General case' 0 N--CA 1.512 2.636 0 O-C-N 122.097 -0.377 . . . . 0.0 110.766 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 56.8 -87.25 0.02 OUTLIER 'General case' 0 N--CA 1.513 2.701 0 C-N-CA 123.233 0.613 . . . . 0.0 110.289 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -133.38 44.58 1.18 Allowed Glycine 0 N--CA 1.502 3.078 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 178.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . 0.599 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 18.6 t80 70.51 64.97 0.2 Allowed 'General case' 0 N--CA 1.505 2.315 0 CA-C-O 121.992 0.901 . . . . 0.0 109.491 -179.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.591 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -135.28 152.53 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.713 0 O-C-N 121.865 -0.522 . . . . 0.0 109.858 179.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.1 m -62.02 109.2 1.21 Allowed 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 121.242 0.544 . . . . 0.0 110.108 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.4 m -91.0 149.27 21.91 Favored 'General case' 0 N--CA 1.512 2.651 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.342 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -74.67 -173.35 1.79 Allowed 'General case' 0 N--CA 1.503 2.221 0 CA-C-O 121.231 0.538 . . . . 0.0 110.992 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.659 HG12 ' OXT' ' A' ' 426' ' ' GLU . 11.8 tt -174.78 -50.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.886 0 O-C-N 121.884 -0.51 . . . . 0.0 110.99 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 424' ' ' ILE . 8.9 m-20 61.93 58.26 1.95 Allowed 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . 0.659 ' OXT' HG12 ' A' ' 424' ' ' ILE . 1.1 mp0 . . . . . 0 N--CA 1.521 3.081 0 C-N-CA 123.962 0.905 . . . . 0.0 110.658 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.556 1.189 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.53 179.05 6.8 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.857 2.371 . . . . 0.0 112.866 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -46.73 133.91 10.21 Favored 'General case' 0 N--CA 1.521 3.083 0 CA-C-O 121.106 0.479 . . . . 0.0 111.271 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 95.38 -49.28 1.89 Allowed Glycine 0 N--CA 1.507 3.397 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 -177.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -81.14 88.42 6.0 Favored 'General case' 0 N--CA 1.499 2.006 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 178.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.47 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -95.39 -176.35 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.28 0 O-C-N 121.522 -0.737 . . . . 0.0 110.417 -178.857 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.2 OUTLIER -104.98 139.01 40.31 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.591 -0.693 . . . . 0.0 109.414 179.704 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.51 -173.54 2.5 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -54.07 119.25 4.82 Favored 'General case' 0 N--CA 1.515 2.799 0 CA-C-O 121.113 0.482 . . . . 0.0 110.399 -179.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.13 -4.44 31.7 Favored Glycine 0 N--CA 1.506 3.34 0 CA-C-O 118.775 -1.014 . . . . 0.0 111.862 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 22.7 t80 68.15 66.86 0.34 Allowed 'General case' 0 N--CA 1.508 2.428 0 CA-C-N 119.505 1.652 . . . . 0.0 109.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.79 152.83 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.575 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.7 t -70.93 115.75 10.43 Favored 'General case' 0 N--CA 1.511 2.614 0 CA-C-O 121.398 0.618 . . . . 0.0 111.764 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . 0.47 ' HB ' HD13 ' A' ' 414' ' ' ILE . 1.7 m -96.63 162.9 13.25 Favored 'General case' 0 N--CA 1.513 2.685 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -63.32 -173.8 0.07 Allowed 'General case' 0 N--CA 1.504 2.264 0 CA-C-O 121.644 0.735 . . . . 0.0 110.971 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -79.63 -34.63 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 121.509 -0.744 . . . . 0.0 109.876 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 57.71 52.32 8.34 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-O 121.771 0.796 . . . . 0.0 110.168 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.507 2.386 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.878 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 CA--C 1.556 1.2 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -75.68 -168.97 0.59 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.982 2.455 . . . . 0.0 112.477 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -47.11 130.4 12.59 Favored 'General case' 0 N--CA 1.519 2.99 0 CA-C-O 121.031 0.443 . . . . 0.0 111.183 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . 0.523 ' CA ' HD12 ' A' ' 424' ' ' ILE . . . 97.71 -49.05 1.46 Allowed Glycine 0 N--CA 1.508 3.475 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -80.7 88.57 5.76 Favored 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.469 ' C ' HD13 ' A' ' 414' ' ' ILE . 0.0 OUTLIER -86.95 -172.97 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.338 0 CA-C-O 121.352 0.596 . . . . 0.0 112.474 -176.784 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.595 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -104.44 153.96 20.46 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.853 -0.53 . . . . 0.0 109.925 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . 0.445 ' HB2' ' OG1' ' A' ' 422' ' ' THR . 0.4 OUTLIER -106.25 -171.54 1.92 Allowed 'General case' 0 N--CA 1.514 2.766 0 O-C-N 121.937 -0.477 . . . . 0.0 111.003 179.623 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -51.29 130.17 26.24 Favored 'General case' 0 N--CA 1.515 2.789 0 CA-C-O 121.16 0.505 . . . . 0.0 110.855 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 96.81 -6.12 64.43 Favored Glycine 0 N--CA 1.507 3.409 0 CA-C-O 119.036 -0.869 . . . . 0.0 111.453 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 25.9 t80 68.43 71.41 0.3 Allowed 'General case' 0 N--CA 1.509 2.479 0 CA-C-N 119.092 1.446 . . . . 0.0 109.229 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.509 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.0 pp -137.6 153.94 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.497 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.718 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . 0.595 ' HA ' HD22 ' A' ' 415' ' ' LEU . 0.1 OUTLIER -60.0 124.98 21.9 Favored 'General case' 0 N--CA 1.516 2.848 0 CA-C-O 121.013 0.435 . . . . 0.0 111.382 -178.623 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . 0.445 ' OG1' ' HB2' ' A' ' 416' ' ' ASP . 6.5 m -134.3 150.03 50.94 Favored 'General case' 0 N--CA 1.509 2.506 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -91.82 143.61 26.34 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 122.405 1.098 . . . . 0.0 111.04 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.523 HD12 ' CA ' ' A' ' 412' ' ' GLY . 20.9 tt -55.04 -37.06 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.921 178.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 55.25 53.43 10.05 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-O 121.692 0.758 . . . . 0.0 110.416 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.478 0 O-C-N 121.931 -0.481 . . . . 0.0 110.045 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 1.2 m . . . . . 0 CA--C 1.558 1.288 0 N-CA-C 110.61 -0.144 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -76.17 177.84 8.25 Favored 'Trans proline' 0 N--CA 1.496 1.676 0 C-N-CA 123.007 2.471 . . . . 0.0 113.282 -178.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.82 134.02 25.75 Favored 'General case' 0 N--CA 1.518 2.959 0 CA-C-O 121.032 0.444 . . . . 0.0 111.194 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.49 -43.81 2.31 Favored Glycine 0 N--CA 1.508 3.484 0 N-CA-C 108.761 -1.735 . . . . 0.0 108.761 -177.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . 0.522 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 74.6 m-85 -85.74 75.77 10.03 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 2.1 pt -67.08 172.69 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.527 3.413 0 O-C-N 121.568 -0.708 . . . . 0.0 112.32 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.417 HD22 ' N ' ' A' ' 415' ' ' LEU . 3.9 mm? -105.48 119.74 39.87 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 178.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . 0.403 ' CB ' HD11 ' A' ' 420' ' ' ILE . 0.1 OUTLIER -82.98 -170.56 3.09 Favored 'General case' 0 N--CA 1.514 2.77 0 O-C-N 122.004 -0.435 . . . . 0.0 111.416 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -49.44 123.01 6.86 Favored 'General case' 0 N--CA 1.516 2.839 0 CA-C-O 121.202 0.525 . . . . 0.0 110.866 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 95.03 -0.24 64.16 Favored Glycine 0 N--CA 1.507 3.382 0 CA-C-O 118.909 -0.939 . . . . 0.0 111.794 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . 0.412 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 20.6 t80 66.44 71.44 0.4 Allowed 'General case' 0 N--CA 1.506 2.352 0 CA-C-N 119.306 1.553 . . . . 0.0 109.34 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.578 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.15 151.0 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.479 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.3 m -63.74 104.1 0.63 Allowed 'General case' 0 N--CA 1.511 2.607 0 CA-C-O 121.532 0.682 . . . . 0.0 112.681 -176.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 3.5 m -89.19 155.41 19.43 Favored 'General case' 0 N--CA 1.516 2.861 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.57 -171.57 0.28 Allowed 'General case' 0 N--CA 1.506 2.347 0 CA-C-O 121.455 0.645 . . . . 0.0 111.457 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.516 HG23 ' N ' ' A' ' 425' ' ' ASP . 3.6 tt -115.84 -139.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.283 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 424' ' ' ILE . 17.3 m-20 64.16 83.0 0.17 Allowed 'General case' 0 N--CA 1.512 2.649 0 CA-C-N 120.064 1.302 . . . . 0.0 110.131 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.522 3.143 0 C-N-CA 123.722 0.809 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 22.3 m . . . . . 0 CA--C 1.556 1.199 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.92 -174.57 2.23 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 122.866 2.378 . . . . 0.0 112.764 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.99 132.44 9.34 Favored 'General case' 0 N--CA 1.52 3.052 0 C-N-CA 122.756 0.422 . . . . 0.0 111.492 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -49.59 2.13 Favored Glycine 0 N--CA 1.505 3.236 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -178.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 37.4 m-85 -77.41 85.68 3.81 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.27 -172.86 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.521 3.081 0 O-C-N 121.778 -0.576 . . . . 0.0 110.805 -178.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.417 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.9 OUTLIER -104.13 121.18 42.7 Favored 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.28 -174.41 5.21 Favored 'General case' 0 N--CA 1.512 2.657 0 O-C-N 121.956 -0.465 . . . . 0.0 111.1 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -54.01 116.43 2.56 Favored 'General case' 0 N--CA 1.513 2.717 0 CA-C-O 121.215 0.531 . . . . 0.0 110.124 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.57 -3.93 30.92 Favored Glycine 0 N--CA 1.507 3.368 0 CA-C-O 118.773 -1.015 . . . . 0.0 111.776 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 21.0 t80 68.26 69.21 0.32 Allowed 'General case' 0 N--CA 1.505 2.286 0 CA-C-N 119.49 1.645 . . . . 0.0 109.916 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.599 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -139.09 151.99 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.501 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.8 t -71.11 114.17 8.9 Favored 'General case' 0 N--CA 1.512 2.652 0 O-C-N 121.613 -0.679 . . . . 0.0 110.689 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.17 -173.92 3.07 Favored 'General case' 0 N--CA 1.516 2.863 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.24 -172.2 0.87 Allowed 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.623 -0.673 . . . . 0.0 111.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.454 HG12 ' HB2' ' A' ' 426' ' ' GLU . 0.4 OUTLIER -84.91 -41.25 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.766 -0.583 . . . . 0.0 110.015 -179.903 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 53.59 47.19 24.46 Favored 'General case' 0 N--CA 1.511 2.623 0 CA-C-O 121.531 0.681 . . . . 0.0 111.027 178.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . 0.454 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.871 -0.518 . . . . 0.0 110.113 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 CA--C 1.557 1.232 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -76.92 -170.7 0.96 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 123.009 2.472 . . . . 0.0 112.605 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -47.2 130.21 12.8 Favored 'General case' 0 N--CA 1.521 3.086 0 CA-C-O 120.878 0.37 . . . . 0.0 111.063 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . 0.459 ' HA3' HG13 ' A' ' 424' ' ' ILE . . . 95.27 -48.73 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -78.71 86.65 4.65 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 415' ' ' LEU . 8.4 pt -89.7 -170.93 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.166 0 O-C-N 121.565 -0.71 . . . . 0.0 111.523 -178.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.514 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -111.86 120.57 42.41 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.45 -173.94 2.52 Favored 'General case' 0 N--CA 1.514 2.742 0 O-C-N 122.12 -0.362 . . . . 0.0 111.341 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 49.63 -94.79 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.777 0 C-N-CA 123.527 0.731 . . . . 0.0 111.075 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -129.39 50.72 0.88 Allowed Glycine 0 N--CA 1.503 3.15 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 178.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . 0.514 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 16.6 t80 72.42 69.5 0.14 Allowed 'General case' 0 N--CA 1.506 2.364 0 CA-C-O 121.84 0.829 . . . . 0.0 109.768 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.79 153.77 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.687 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -63.92 104.32 0.69 Allowed 'General case' 0 N--CA 1.511 2.61 0 CA-C-O 121.578 0.704 . . . . 0.0 111.76 -177.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.77 167.88 12.93 Favored 'General case' 0 N--CA 1.517 2.905 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -68.67 -172.92 0.4 Allowed 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.538 -0.726 . . . . 0.0 111.131 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.48 HG12 ' HB2' ' A' ' 426' ' ' GLU . 2.6 tt -105.8 -54.19 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.68 0 O-C-N 121.66 -0.65 . . . . 0.0 110.929 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 53.31 48.36 22.2 Favored 'General case' 0 N--CA 1.512 2.659 0 CA-C-O 121.458 0.647 . . . . 0.0 111.168 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . 0.48 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.512 2.629 0 O-C-N 121.81 -0.556 . . . . 0.0 109.969 179.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . 0.412 ' SG ' HD21 ' A' ' 415' ' ' LEU . 2.6 m . . . . . 0 CA--C 1.552 1.048 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . 0.441 ' HG2' ' CD2' ' A' ' 413' ' ' TYR . 33.9 Cg_endo -76.44 170.26 20.31 Favored 'Trans proline' 0 CA--C 1.553 1.457 0 C-N-CA 122.695 2.263 . . . . 0.0 112.385 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -49.19 132.36 19.58 Favored 'General case' 0 N--CA 1.518 2.928 0 CA-C-O 121.05 0.452 . . . . 0.0 111.55 -179.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.1 -43.49 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -178.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . 0.441 ' CD2' ' HG2' ' A' ' 410' ' ' PRO . 97.2 m-85 -76.15 83.95 2.98 Favored 'General case' 0 N--CA 1.503 2.191 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.32 153.97 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.135 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.672 -178.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.412 HD21 ' SG ' ' A' ' 409' ' ' CYS . 0.5 OUTLIER -96.28 116.82 29.62 Favored 'General case' 0 N--CA 1.505 2.323 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.491 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -170.73 2.81 Favored 'General case' 0 N--CA 1.513 2.706 0 O-C-N 121.824 -0.547 . . . . 0.0 111.027 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -50.95 127.95 20.07 Favored 'General case' 0 N--CA 1.511 2.598 0 CA-C-O 121.353 0.597 . . . . 0.0 110.75 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 92.75 -0.37 70.08 Favored Glycine 0 N--CA 1.505 3.242 0 CA-C-O 118.57 -1.128 . . . . 0.0 112.187 -179.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 33.6 t80 66.89 70.07 0.39 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-N 119.785 1.792 . . . . 0.0 109.196 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.562 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -134.4 152.33 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.543 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 56.9 m -70.05 97.99 1.24 Allowed 'General case' 0 N--CA 1.508 2.452 0 N-CA-C 112.523 0.564 . . . . 0.0 112.523 -177.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.22 -170.62 3.13 Favored 'General case' 0 N--CA 1.516 2.858 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -72.86 -178.63 2.82 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.075 -1.015 . . . . 0.0 111.354 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.474 HG12 ' HB2' ' A' ' 426' ' ' GLU . 5.8 tt -109.78 -52.85 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.682 0 O-C-N 121.924 -0.485 . . . . 0.0 110.867 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 58.32 63.03 1.83 Allowed 'General case' 0 N--CA 1.511 2.603 0 CA-C-O 121.687 0.756 . . . . 0.0 110.511 179.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . 0.474 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.511 2.613 0 O-C-N 122.028 -0.42 . . . . 0.0 110.169 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 11.9 m . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . 0.421 ' HG2' ' CD1' ' A' ' 413' ' ' TYR . 33.4 Cg_endo -76.31 -179.29 5.13 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.84 2.36 . . . . 0.0 112.879 -179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -50.25 132.07 24.06 Favored 'General case' 0 N--CA 1.519 3.018 0 CA-C-O 121.002 0.43 . . . . 0.0 111.395 -179.257 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.05 -45.25 1.81 Allowed Glycine 0 N--CA 1.508 3.48 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -178.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . 0.421 ' CD1' ' HG2' ' A' ' 410' ' ' PRO . 13.9 m-85 -83.06 88.27 6.88 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.456 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -101.2 -172.59 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.316 0 O-C-N 121.584 -0.698 . . . . 0.0 111.311 -177.83 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.435 HD12 ' C ' ' A' ' 419' ' ' PHE . 3.4 mm? -95.73 126.64 41.14 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -75.35 -173.6 2.12 Favored 'General case' 0 N--CA 1.515 2.775 0 O-C-N 121.979 -0.451 . . . . 0.0 110.758 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -53.97 -34.04 58.64 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 121.678 -0.639 . . . . 0.0 111.125 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -88.95 10.39 72.95 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 118.808 -0.995 . . . . 0.0 112.542 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . 0.435 ' C ' HD12 ' A' ' 415' ' ' LEU . 12.2 t80 61.05 60.64 1.77 Allowed 'General case' 0 N--CA 1.508 2.466 0 CA-C-N 119.726 1.763 . . . . 0.0 110.038 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.533 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -138.35 159.32 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.667 0 O-C-N 121.779 -0.575 . . . . 0.0 109.636 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.1 t -64.65 103.96 0.75 Allowed 'General case' 0 N--CA 1.512 2.628 0 CA-C-O 121.48 0.657 . . . . 0.0 111.13 -178.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . 0.456 ' HB ' HD13 ' A' ' 414' ' ' ILE . 5.8 m -86.21 166.12 15.97 Favored 'General case' 0 N--CA 1.514 2.756 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -65.76 -172.52 0.13 Allowed 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 121.345 0.593 . . . . 0.0 110.795 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -78.57 -33.08 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.653 0 O-C-N 121.538 -0.726 . . . . 0.0 110.13 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 54.74 46.72 24.03 Favored 'General case' 0 N--CA 1.514 2.729 0 CA-C-O 121.656 0.741 . . . . 0.0 110.25 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 . . . . . 0 N--CA 1.507 2.424 0 O-C-N 122.042 -0.412 . . . . 0.0 110.231 -179.811 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.552 1.042 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -76.92 -176.41 3.16 Favored 'Trans proline' 0 CA--C 1.556 1.585 0 C-N-CA 122.627 2.218 . . . . 0.0 112.214 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -51.49 131.82 29.44 Favored 'General case' 0 N--CA 1.517 2.883 0 CA-C-O 121.003 0.43 . . . . 0.0 111.251 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.35 -40.16 2.56 Favored Glycine 0 N--CA 1.507 3.394 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . 0.535 ' HA ' HD11 ' A' ' 424' ' ' ILE . 82.0 m-85 -83.47 84.99 7.32 Favored 'General case' 0 N--CA 1.5 2.037 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 6.1 pt -83.01 173.42 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.519 3.007 0 CA-C-O 121.463 0.649 . . . . 0.0 111.749 -178.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.458 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -100.85 154.05 18.97 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-O 121.209 0.528 . . . . 0.0 109.888 179.055 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.7 -168.14 3.02 Favored 'General case' 0 N--CA 1.51 2.572 0 O-C-N 122.085 -0.384 . . . . 0.0 110.864 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 54.94 -90.79 0.03 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.319 0.648 . . . . 0.0 110.66 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -131.57 46.27 1.08 Allowed Glycine 0 N--CA 1.503 3.104 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 28.8 t80 70.65 67.3 0.19 Allowed 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 122.135 0.969 . . . . 0.0 109.254 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -138.96 156.18 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.719 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.971 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . 0.458 ' HA ' HD22 ' A' ' 415' ' ' LEU . 1.6 t -62.04 118.48 7.36 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 122.086 -0.384 . . . . 0.0 110.752 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 85.9 m -109.3 139.31 44.41 Favored 'General case' 0 N--CA 1.508 2.472 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -74.89 -174.78 2.31 Favored 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.478 0.656 . . . . 0.0 111.346 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.535 HD11 ' HA ' ' A' ' 413' ' ' TYR . 2.2 mm -121.38 -147.46 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.371 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -115.81 39.4 3.04 Favored 'General case' 0 N--CA 1.505 2.324 0 O-C-N 121.296 -0.877 . . . . 0.0 108.983 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 . . . . . 0 N--CA 1.508 2.453 0 O-C-N 122.019 -0.426 . . . . 0.0 110.076 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.557 1.248 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -77.14 -167.8 0.51 Allowed 'Trans proline' 0 N--CA 1.5 1.908 0 C-N-CA 123.247 2.631 . . . . 0.0 112.471 -179.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -47.54 131.0 14.19 Favored 'General case' 0 N--CA 1.521 3.081 0 CA-C-O 121.002 0.429 . . . . 0.0 111.125 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . 0.581 ' HA3' HD12 ' A' ' 424' ' ' ILE . . . 96.47 -48.53 1.69 Allowed Glycine 0 N--CA 1.509 3.546 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -82.88 86.49 6.93 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.98 -168.51 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.366 0 O-C-N 121.498 -0.751 . . . . 0.0 112.691 -176.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.458 HD22 ' N ' ' A' ' 415' ' ' LEU . 3.9 mm? -106.1 141.13 37.98 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -133.8 -175.51 3.86 Favored 'General case' 0 N--CA 1.516 2.871 0 O-C-N 121.873 -0.517 . . . . 0.0 111.469 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 51.19 -96.65 0.05 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.352 0.661 . . . . 0.0 110.905 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -124.57 48.2 0.97 Allowed Glycine 0 N--CA 1.502 3.083 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . 0.434 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 17.8 t80 70.84 70.9 0.19 Allowed 'General case' 0 N--CA 1.505 2.306 0 CA-C-O 121.917 0.865 . . . . 0.0 109.801 -179.271 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.558 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -132.88 151.35 34.18 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.621 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.88 116.81 4.02 Favored 'General case' 0 N--CA 1.514 2.766 0 CA-C-O 121.402 0.62 . . . . 0.0 111.904 -177.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 31.0 m -123.41 152.05 41.99 Favored 'General case' 0 N--CA 1.51 2.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.27 -162.56 0.3 Allowed 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.454 0.645 . . . . 0.0 111.252 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . 0.581 HD12 ' HA3' ' A' ' 412' ' ' GLY . 1.1 tt -81.42 -35.74 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.928 -0.483 . . . . 0.0 110.294 -179.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 53.86 55.98 7.73 Favored 'General case' 0 N--CA 1.51 2.562 0 CA-C-O 121.421 0.629 . . . . 0.0 110.146 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 N--CA 1.521 3.099 0 C-N-CA 123.879 0.872 . . . . 0.0 110.423 -179.537 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 10.8 m . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -76.95 -171.07 1.04 Allowed 'Trans proline' 0 N--CA 1.499 1.829 0 C-N-CA 123.003 2.469 . . . . 0.0 112.765 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.3 131.15 8.17 Favored 'General case' 0 N--CA 1.521 3.084 0 C-N-CA 122.806 0.442 . . . . 0.0 111.479 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -50.87 2.12 Favored Glycine 0 N--CA 1.504 3.208 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -177.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -78.49 87.34 4.48 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 414' ' ' ILE . . . . . 0.489 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -102.8 -170.67 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.153 0 O-C-N 121.53 -0.731 . . . . 0.0 110.984 -178.602 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 415' ' ' LEU . . . . . 0.523 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -100.55 123.1 44.3 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.94 -169.45 0.91 Allowed 'General case' 0 N--CA 1.517 2.883 0 O-C-N 121.923 -0.486 . . . . 0.0 111.097 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -51.98 -37.75 54.2 Favored 'General case' 0 N--CA 1.519 3.01 0 O-C-N 121.728 -0.608 . . . . 0.0 111.878 -179.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -91.05 14.18 64.19 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 119.002 -0.888 . . . . 0.0 112.209 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 419' ' ' PHE . . . . . 0.523 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 10.8 t80 58.3 62.55 1.97 Allowed 'General case' 0 N--CA 1.506 2.33 0 CA-C-N 119.347 1.574 . . . . 0.0 110.08 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 420' ' ' ILE . . . . . 0.524 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.65 159.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.511 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.686 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.3 t -65.7 102.84 0.79 Allowed 'General case' 0 N--CA 1.511 2.604 0 CA-C-O 121.464 0.65 . . . . 0.0 111.167 -178.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 422' ' ' THR . . . . . 0.489 ' HB ' HD13 ' A' ' 414' ' ' ILE . 7.8 m -84.53 168.41 15.44 Favored 'General case' 0 N--CA 1.514 2.75 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 423' ' ' ASP . . . . . 0.4 ' N ' HG22 ' A' ' 422' ' ' THR . 10.5 m-20 -64.81 -171.75 0.07 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 121.585 -0.697 . . . . 0.0 110.589 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -81.98 -41.82 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.597 0 O-C-N 121.324 -0.86 . . . . 0.0 109.823 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 51.97 46.02 27.29 Favored 'General case' 0 N--CA 1.512 2.665 0 CA-C-O 121.525 0.678 . . . . 0.0 111.064 178.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.91 -0.494 . . . . 0.0 110.032 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 15.3 m . . . . . 0 CA--C 1.555 1.145 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -77.77 -172.9 1.61 Allowed 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.956 2.437 . . . . 0.0 112.731 -179.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.26 134.23 23.02 Favored 'General case' 0 N--CA 1.518 2.961 0 CA-C-O 121.031 0.443 . . . . 0.0 111.141 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 96.38 -43.87 2.05 Favored Glycine 0 N--CA 1.509 3.517 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . 0.466 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 51.3 m-85 -84.89 87.44 7.34 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.81 -176.32 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.14 0 O-C-N 121.582 -0.699 . . . . 0.0 111.715 -177.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.599 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.1 mm? -103.1 116.87 33.34 Favored 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -124.5 -172.17 2.5 Favored 'General case' 0 N--CA 1.512 2.636 0 O-C-N 122.097 -0.377 . . . . 0.0 110.766 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 56.8 -87.25 0.02 OUTLIER 'General case' 0 N--CA 1.513 2.701 0 C-N-CA 123.233 0.613 . . . . 0.0 110.289 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -133.38 44.58 1.18 Allowed Glycine 0 N--CA 1.502 3.078 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 178.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . 0.599 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 18.6 t80 70.51 64.97 0.2 Allowed 'General case' 0 N--CA 1.505 2.315 0 CA-C-O 121.992 0.901 . . . . 0.0 109.491 -179.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.591 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -135.28 152.53 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.713 0 O-C-N 121.865 -0.522 . . . . 0.0 109.858 179.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.1 m -62.02 109.2 1.21 Allowed 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 121.242 0.544 . . . . 0.0 110.108 -178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 5.4 m -91.0 149.27 21.91 Favored 'General case' 0 N--CA 1.512 2.651 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.342 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -74.67 -173.35 1.79 Allowed 'General case' 0 N--CA 1.503 2.221 0 CA-C-O 121.231 0.538 . . . . 0.0 110.992 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.659 HG12 ' OXT' ' A' ' 426' ' ' GLU . 11.8 tt -174.78 -50.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.886 0 O-C-N 121.884 -0.51 . . . . 0.0 110.99 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 424' ' ' ILE . 8.9 m-20 61.93 58.26 1.95 Allowed 'General case' 0 N--CA 1.508 2.438 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . 0.659 ' OXT' HG12 ' A' ' 424' ' ' ILE . 1.1 mp0 . . . . . 0 N--CA 1.521 3.081 0 C-N-CA 123.962 0.905 . . . . 0.0 110.658 -179.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.556 1.189 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.53 179.05 6.8 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.857 2.371 . . . . 0.0 112.866 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -46.73 133.91 10.21 Favored 'General case' 0 N--CA 1.521 3.083 0 CA-C-O 121.106 0.479 . . . . 0.0 111.271 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 95.38 -49.28 1.89 Allowed Glycine 0 N--CA 1.507 3.397 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 -177.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -81.14 88.42 6.0 Favored 'General case' 0 N--CA 1.499 2.006 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 178.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.47 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -95.39 -176.35 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.28 0 O-C-N 121.522 -0.737 . . . . 0.0 110.417 -178.857 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.43 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.2 OUTLIER -104.98 139.01 40.31 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.591 -0.693 . . . . 0.0 109.414 179.704 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.51 -173.54 2.5 Favored 'General case' 0 N--CA 1.51 2.527 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -54.07 119.25 4.82 Favored 'General case' 0 N--CA 1.515 2.799 0 CA-C-O 121.113 0.482 . . . . 0.0 110.399 -179.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.13 -4.44 31.7 Favored Glycine 0 N--CA 1.506 3.34 0 CA-C-O 118.775 -1.014 . . . . 0.0 111.862 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 22.7 t80 68.15 66.86 0.34 Allowed 'General case' 0 N--CA 1.508 2.428 0 CA-C-N 119.505 1.652 . . . . 0.0 109.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.79 152.83 31.58 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.575 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.7 t -70.93 115.75 10.43 Favored 'General case' 0 N--CA 1.511 2.614 0 CA-C-O 121.398 0.618 . . . . 0.0 111.764 -178.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . 0.47 ' HB ' HD13 ' A' ' 414' ' ' ILE . 1.7 m -96.63 162.9 13.25 Favored 'General case' 0 N--CA 1.513 2.685 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -63.32 -173.8 0.07 Allowed 'General case' 0 N--CA 1.504 2.264 0 CA-C-O 121.644 0.735 . . . . 0.0 110.971 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -79.63 -34.63 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.344 0 O-C-N 121.509 -0.744 . . . . 0.0 109.876 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 57.71 52.32 8.34 Favored 'General case' 0 N--CA 1.509 2.51 0 CA-C-O 121.771 0.796 . . . . 0.0 110.168 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.507 2.386 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.878 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 CA--C 1.556 1.2 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -75.68 -168.97 0.59 Allowed 'Trans proline' 0 N--CA 1.498 1.771 0 C-N-CA 122.982 2.455 . . . . 0.0 112.477 -178.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -47.11 130.4 12.59 Favored 'General case' 0 N--CA 1.519 2.99 0 CA-C-O 121.031 0.443 . . . . 0.0 111.183 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . 0.523 ' CA ' HD12 ' A' ' 424' ' ' ILE . . . 97.71 -49.05 1.46 Allowed Glycine 0 N--CA 1.508 3.475 0 N-CA-C 108.511 -1.836 . . . . 0.0 108.511 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -80.7 88.57 5.76 Favored 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 178.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.469 ' C ' HD13 ' A' ' 414' ' ' ILE . 0.0 OUTLIER -86.95 -172.97 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.338 0 CA-C-O 121.352 0.596 . . . . 0.0 112.474 -176.784 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.595 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -104.44 153.96 20.46 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.853 -0.53 . . . . 0.0 109.925 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . 0.445 ' HB2' ' OG1' ' A' ' 422' ' ' THR . 0.4 OUTLIER -106.25 -171.54 1.92 Allowed 'General case' 0 N--CA 1.514 2.766 0 O-C-N 121.937 -0.477 . . . . 0.0 111.003 179.623 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -51.29 130.17 26.24 Favored 'General case' 0 N--CA 1.515 2.789 0 CA-C-O 121.16 0.505 . . . . 0.0 110.855 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 96.81 -6.12 64.43 Favored Glycine 0 N--CA 1.507 3.409 0 CA-C-O 119.036 -0.869 . . . . 0.0 111.453 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 25.9 t80 68.43 71.41 0.3 Allowed 'General case' 0 N--CA 1.509 2.479 0 CA-C-N 119.092 1.446 . . . . 0.0 109.229 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.509 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.0 pp -137.6 153.94 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.497 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.718 179.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . 0.595 ' HA ' HD22 ' A' ' 415' ' ' LEU . 0.1 OUTLIER -60.0 124.98 21.9 Favored 'General case' 0 N--CA 1.516 2.848 0 CA-C-O 121.013 0.435 . . . . 0.0 111.382 -178.623 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . 0.445 ' OG1' ' HB2' ' A' ' 416' ' ' ASP . 6.5 m -134.3 150.03 50.94 Favored 'General case' 0 N--CA 1.509 2.506 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -91.82 143.61 26.34 Favored 'General case' 0 N--CA 1.497 1.889 0 CA-C-O 122.405 1.098 . . . . 0.0 111.04 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.523 HD12 ' CA ' ' A' ' 412' ' ' GLY . 20.9 tt -55.04 -37.06 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.299 0 CA-C-N 114.314 -1.312 . . . . 0.0 110.921 178.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 55.25 53.43 10.05 Favored 'General case' 0 N--CA 1.512 2.643 0 CA-C-O 121.692 0.758 . . . . 0.0 110.416 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.509 2.478 0 O-C-N 121.931 -0.481 . . . . 0.0 110.045 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 413' ' ' TYR . 1.2 m . . . . . 0 CA--C 1.558 1.288 0 N-CA-C 110.61 -0.144 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -76.17 177.84 8.25 Favored 'Trans proline' 0 N--CA 1.496 1.676 0 C-N-CA 123.007 2.471 . . . . 0.0 113.282 -178.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -50.82 134.02 25.75 Favored 'General case' 0 N--CA 1.518 2.959 0 CA-C-O 121.032 0.444 . . . . 0.0 111.194 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.49 -43.81 2.31 Favored Glycine 0 N--CA 1.508 3.484 0 N-CA-C 108.761 -1.735 . . . . 0.0 108.761 -177.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . 0.522 ' HB2' ' HB3' ' A' ' 409' ' ' CYS . 74.6 m-85 -85.74 75.77 10.03 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 2.1 pt -67.08 172.69 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.527 3.413 0 O-C-N 121.568 -0.708 . . . . 0.0 112.32 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.417 HD22 ' N ' ' A' ' 415' ' ' LEU . 3.9 mm? -105.48 119.74 39.87 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 107.54 -1.281 . . . . 0.0 107.54 178.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . 0.403 ' CB ' HD11 ' A' ' 420' ' ' ILE . 0.1 OUTLIER -82.98 -170.56 3.09 Favored 'General case' 0 N--CA 1.514 2.77 0 O-C-N 122.004 -0.435 . . . . 0.0 111.416 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -49.44 123.01 6.86 Favored 'General case' 0 N--CA 1.516 2.839 0 CA-C-O 121.202 0.525 . . . . 0.0 110.866 -179.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 95.03 -0.24 64.16 Favored Glycine 0 N--CA 1.507 3.382 0 CA-C-O 118.909 -0.939 . . . . 0.0 111.794 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . 0.412 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 20.6 t80 66.44 71.44 0.4 Allowed 'General case' 0 N--CA 1.506 2.352 0 CA-C-N 119.306 1.553 . . . . 0.0 109.34 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.578 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.15 151.0 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.479 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 1.3 m -63.74 104.1 0.63 Allowed 'General case' 0 N--CA 1.511 2.607 0 CA-C-O 121.532 0.682 . . . . 0.0 112.681 -176.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 3.5 m -89.19 155.41 19.43 Favored 'General case' 0 N--CA 1.516 2.861 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.57 -171.57 0.28 Allowed 'General case' 0 N--CA 1.506 2.347 0 CA-C-O 121.455 0.645 . . . . 0.0 111.457 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.516 HG23 ' N ' ' A' ' 425' ' ' ASP . 3.6 tt -115.84 -139.03 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.283 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 424' ' ' ILE . 17.3 m-20 64.16 83.0 0.17 Allowed 'General case' 0 N--CA 1.512 2.649 0 CA-C-N 120.064 1.302 . . . . 0.0 110.131 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.522 3.143 0 C-N-CA 123.722 0.809 . . . . 0.0 110.921 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 22.3 m . . . . . 0 CA--C 1.556 1.199 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -76.92 -174.57 2.23 Favored 'Trans proline' 0 N--CA 1.498 1.753 0 C-N-CA 122.866 2.378 . . . . 0.0 112.764 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.99 132.44 9.34 Favored 'General case' 0 N--CA 1.52 3.052 0 C-N-CA 122.756 0.422 . . . . 0.0 111.492 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -49.59 2.13 Favored Glycine 0 N--CA 1.505 3.236 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -178.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 37.4 m-85 -77.41 85.68 3.81 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.27 -172.86 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.521 3.081 0 O-C-N 121.778 -0.576 . . . . 0.0 110.805 -178.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.417 ' HA ' ' O ' ' A' ' 420' ' ' ILE . 0.9 OUTLIER -104.13 121.18 42.7 Favored 'General case' 0 N--CA 1.501 2.097 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.902 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.28 -174.41 5.21 Favored 'General case' 0 N--CA 1.512 2.657 0 O-C-N 121.956 -0.465 . . . . 0.0 111.1 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -54.01 116.43 2.56 Favored 'General case' 0 N--CA 1.513 2.717 0 CA-C-O 121.215 0.531 . . . . 0.0 110.124 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 109.57 -3.93 30.92 Favored Glycine 0 N--CA 1.507 3.368 0 CA-C-O 118.773 -1.015 . . . . 0.0 111.776 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 21.0 t80 68.26 69.21 0.32 Allowed 'General case' 0 N--CA 1.505 2.286 0 CA-C-N 119.49 1.645 . . . . 0.0 109.916 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.599 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -139.09 151.99 23.66 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.501 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.8 t -71.11 114.17 8.9 Favored 'General case' 0 N--CA 1.512 2.652 0 O-C-N 121.613 -0.679 . . . . 0.0 110.689 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -95.17 -173.92 3.07 Favored 'General case' 0 N--CA 1.516 2.863 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.24 -172.2 0.87 Allowed 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.623 -0.673 . . . . 0.0 111.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.454 HG12 ' HB2' ' A' ' 426' ' ' GLU . 0.4 OUTLIER -84.91 -41.25 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.669 0 O-C-N 121.766 -0.583 . . . . 0.0 110.015 -179.903 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 53.59 47.19 24.46 Favored 'General case' 0 N--CA 1.511 2.623 0 CA-C-O 121.531 0.681 . . . . 0.0 111.027 178.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . 0.454 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.871 -0.518 . . . . 0.0 110.113 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 CA--C 1.557 1.232 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -76.92 -170.7 0.96 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 123.009 2.472 . . . . 0.0 112.605 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -47.2 130.21 12.8 Favored 'General case' 0 N--CA 1.521 3.086 0 CA-C-O 120.878 0.37 . . . . 0.0 111.063 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . 0.459 ' HA3' HG13 ' A' ' 424' ' ' ILE . . . 95.27 -48.73 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -78.71 86.65 4.65 Favored 'General case' 0 N--CA 1.499 2.025 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.411 ' C ' HD22 ' A' ' 415' ' ' LEU . 8.4 pt -89.7 -170.93 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.166 0 O-C-N 121.565 -0.71 . . . . 0.0 111.523 -178.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.514 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -111.86 120.57 42.41 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -117.45 -173.94 2.52 Favored 'General case' 0 N--CA 1.514 2.742 0 O-C-N 122.12 -0.362 . . . . 0.0 111.341 -179.376 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 49.63 -94.79 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.777 0 C-N-CA 123.527 0.731 . . . . 0.0 111.075 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -129.39 50.72 0.88 Allowed Glycine 0 N--CA 1.503 3.15 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 178.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . 0.514 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 16.6 t80 72.42 69.5 0.14 Allowed 'General case' 0 N--CA 1.506 2.364 0 CA-C-O 121.84 0.829 . . . . 0.0 109.768 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -133.79 153.77 37.13 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.687 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -63.92 104.32 0.69 Allowed 'General case' 0 N--CA 1.511 2.61 0 CA-C-O 121.578 0.704 . . . . 0.0 111.76 -177.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.77 167.88 12.93 Favored 'General case' 0 N--CA 1.517 2.905 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -68.67 -172.92 0.4 Allowed 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.538 -0.726 . . . . 0.0 111.131 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.48 HG12 ' HB2' ' A' ' 426' ' ' GLU . 2.6 tt -105.8 -54.19 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.68 0 O-C-N 121.66 -0.65 . . . . 0.0 110.929 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 53.31 48.36 22.2 Favored 'General case' 0 N--CA 1.512 2.659 0 CA-C-O 121.458 0.647 . . . . 0.0 111.168 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . 0.48 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.512 2.629 0 O-C-N 121.81 -0.556 . . . . 0.0 109.969 179.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . 0.412 ' SG ' HD21 ' A' ' 415' ' ' LEU . 2.6 m . . . . . 0 CA--C 1.552 1.048 0 N-CA-C 109.946 -0.391 . . . . 0.0 109.946 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . 0.441 ' HG2' ' CD2' ' A' ' 413' ' ' TYR . 33.9 Cg_endo -76.44 170.26 20.31 Favored 'Trans proline' 0 CA--C 1.553 1.457 0 C-N-CA 122.695 2.263 . . . . 0.0 112.385 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -49.19 132.36 19.58 Favored 'General case' 0 N--CA 1.518 2.928 0 CA-C-O 121.05 0.452 . . . . 0.0 111.55 -179.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.1 -43.49 1.92 Allowed Glycine 0 N--CA 1.505 3.286 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -178.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . 0.441 ' CD2' ' HG2' ' A' ' 410' ' ' PRO . 97.2 m-85 -76.15 83.95 2.98 Favored 'General case' 0 N--CA 1.503 2.191 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.32 153.97 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.522 3.135 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.672 -178.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.412 HD21 ' SG ' ' A' ' 409' ' ' CYS . 0.5 OUTLIER -96.28 116.82 29.62 Favored 'General case' 0 N--CA 1.505 2.323 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.491 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -80.85 -170.73 2.81 Favored 'General case' 0 N--CA 1.513 2.706 0 O-C-N 121.824 -0.547 . . . . 0.0 111.027 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -50.95 127.95 20.07 Favored 'General case' 0 N--CA 1.511 2.598 0 CA-C-O 121.353 0.597 . . . . 0.0 110.75 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 92.75 -0.37 70.08 Favored Glycine 0 N--CA 1.505 3.242 0 CA-C-O 118.57 -1.128 . . . . 0.0 112.187 -179.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 33.6 t80 66.89 70.07 0.39 Allowed 'General case' 0 N--CA 1.507 2.387 0 CA-C-N 119.785 1.792 . . . . 0.0 109.196 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.562 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -134.4 152.33 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.543 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 56.9 m -70.05 97.99 1.24 Allowed 'General case' 0 N--CA 1.508 2.452 0 N-CA-C 112.523 0.564 . . . . 0.0 112.523 -177.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.22 -170.62 3.13 Favored 'General case' 0 N--CA 1.516 2.858 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 176.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -72.86 -178.63 2.82 Favored 'General case' 0 N--CA 1.502 2.161 0 O-C-N 121.075 -1.015 . . . . 0.0 111.354 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.474 HG12 ' HB2' ' A' ' 426' ' ' GLU . 5.8 tt -109.78 -52.85 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.682 0 O-C-N 121.924 -0.485 . . . . 0.0 110.867 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 58.32 63.03 1.83 Allowed 'General case' 0 N--CA 1.511 2.603 0 CA-C-O 121.687 0.756 . . . . 0.0 110.511 179.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . 0.474 ' HB2' HG12 ' A' ' 424' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.511 2.613 0 O-C-N 122.028 -0.42 . . . . 0.0 110.169 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 11.9 m . . . . . 0 CA--C 1.556 1.202 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . 0.421 ' HG2' ' CD1' ' A' ' 413' ' ' TYR . 33.4 Cg_endo -76.31 -179.29 5.13 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.84 2.36 . . . . 0.0 112.879 -179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -50.25 132.07 24.06 Favored 'General case' 0 N--CA 1.519 3.018 0 CA-C-O 121.002 0.43 . . . . 0.0 111.395 -179.257 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 97.05 -45.25 1.81 Allowed Glycine 0 N--CA 1.508 3.48 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -178.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . 0.421 ' CD1' ' HG2' ' A' ' 410' ' ' PRO . 13.9 m-85 -83.06 88.27 6.88 Favored 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.456 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -101.2 -172.59 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.525 3.316 0 O-C-N 121.584 -0.698 . . . . 0.0 111.311 -177.83 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.435 HD12 ' C ' ' A' ' 419' ' ' PHE . 3.4 mm? -95.73 126.64 41.14 Favored 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -75.35 -173.6 2.12 Favored 'General case' 0 N--CA 1.515 2.775 0 O-C-N 121.979 -0.451 . . . . 0.0 110.758 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -53.97 -34.04 58.64 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 121.678 -0.639 . . . . 0.0 111.125 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -88.95 10.39 72.95 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 118.808 -0.995 . . . . 0.0 112.542 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . 0.435 ' C ' HD12 ' A' ' 415' ' ' LEU . 12.2 t80 61.05 60.64 1.77 Allowed 'General case' 0 N--CA 1.508 2.466 0 CA-C-N 119.726 1.763 . . . . 0.0 110.038 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.533 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -138.35 159.32 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.667 0 O-C-N 121.779 -0.575 . . . . 0.0 109.636 179.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 4.1 t -64.65 103.96 0.75 Allowed 'General case' 0 N--CA 1.512 2.628 0 CA-C-O 121.48 0.657 . . . . 0.0 111.13 -178.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . 0.456 ' HB ' HD13 ' A' ' 414' ' ' ILE . 5.8 m -86.21 166.12 15.97 Favored 'General case' 0 N--CA 1.514 2.756 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -65.76 -172.52 0.13 Allowed 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 121.345 0.593 . . . . 0.0 110.795 179.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -78.57 -33.08 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.512 2.653 0 O-C-N 121.538 -0.726 . . . . 0.0 110.13 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 54.74 46.72 24.03 Favored 'General case' 0 N--CA 1.514 2.729 0 CA-C-O 121.656 0.741 . . . . 0.0 110.25 179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 . . . . . 0 N--CA 1.507 2.424 0 O-C-N 122.042 -0.412 . . . . 0.0 110.231 -179.811 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.552 1.042 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -76.92 -176.41 3.16 Favored 'Trans proline' 0 CA--C 1.556 1.585 0 C-N-CA 122.627 2.218 . . . . 0.0 112.214 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -51.49 131.82 29.44 Favored 'General case' 0 N--CA 1.517 2.883 0 CA-C-O 121.003 0.43 . . . . 0.0 111.251 -179.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 98.35 -40.16 2.56 Favored Glycine 0 N--CA 1.507 3.394 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . 0.535 ' HA ' HD11 ' A' ' 424' ' ' ILE . 82.0 m-85 -83.47 84.99 7.32 Favored 'General case' 0 N--CA 1.5 2.037 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 6.1 pt -83.01 173.42 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.519 3.007 0 CA-C-O 121.463 0.649 . . . . 0.0 111.749 -178.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.458 HD22 ' HA ' ' A' ' 421' ' ' CYS . 0.6 OUTLIER -100.85 154.05 18.97 Favored 'General case' 0 N--CA 1.499 2.009 0 CA-C-O 121.209 0.528 . . . . 0.0 109.888 179.055 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.7 -168.14 3.02 Favored 'General case' 0 N--CA 1.51 2.572 0 O-C-N 122.085 -0.384 . . . . 0.0 110.864 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 54.94 -90.79 0.03 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.319 0.648 . . . . 0.0 110.66 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -131.57 46.27 1.08 Allowed Glycine 0 N--CA 1.503 3.104 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 178.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . . . . . . . . . 28.8 t80 70.65 67.3 0.19 Allowed 'General case' 0 N--CA 1.509 2.509 0 CA-C-O 122.135 0.969 . . . . 0.0 109.254 -179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.518 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.2 pp -138.96 156.18 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.513 2.719 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.971 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . 0.458 ' HA ' HD22 ' A' ' 415' ' ' LEU . 1.6 t -62.04 118.48 7.36 Favored 'General case' 0 N--CA 1.515 2.787 0 O-C-N 122.086 -0.384 . . . . 0.0 110.752 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 85.9 m -109.3 139.31 44.41 Favored 'General case' 0 N--CA 1.508 2.472 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -74.89 -174.78 2.31 Favored 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.478 0.656 . . . . 0.0 111.346 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.535 HD11 ' HA ' ' A' ' 413' ' ' TYR . 2.2 mm -121.38 -147.46 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.371 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -115.81 39.4 3.04 Favored 'General case' 0 N--CA 1.505 2.324 0 O-C-N 121.296 -0.877 . . . . 0.0 108.983 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 . . . . . 0 N--CA 1.508 2.453 0 O-C-N 122.019 -0.426 . . . . 0.0 110.076 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.557 1.248 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -77.14 -167.8 0.51 Allowed 'Trans proline' 0 N--CA 1.5 1.908 0 C-N-CA 123.247 2.631 . . . . 0.0 112.471 -179.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -47.54 131.0 14.19 Favored 'General case' 0 N--CA 1.521 3.081 0 CA-C-O 121.002 0.429 . . . . 0.0 111.125 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . 0.581 ' HA3' HD12 ' A' ' 424' ' ' ILE . . . 96.47 -48.53 1.69 Allowed Glycine 0 N--CA 1.509 3.546 0 N-CA-C 108.152 -1.979 . . . . 0.0 108.152 -177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -82.88 86.49 6.93 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.98 -168.51 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.526 3.366 0 O-C-N 121.498 -0.751 . . . . 0.0 112.691 -176.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.458 HD22 ' N ' ' A' ' 415' ' ' LEU . 3.9 mm? -106.1 141.13 37.98 Favored 'General case' 0 N--CA 1.504 2.262 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -133.8 -175.51 3.86 Favored 'General case' 0 N--CA 1.516 2.871 0 O-C-N 121.873 -0.517 . . . . 0.0 111.469 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 51.19 -96.65 0.05 OUTLIER 'General case' 0 N--CA 1.513 2.718 0 C-N-CA 123.352 0.661 . . . . 0.0 110.905 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -124.57 48.2 0.97 Allowed Glycine 0 N--CA 1.502 3.083 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . 0.434 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 17.8 t80 70.84 70.9 0.19 Allowed 'General case' 0 N--CA 1.505 2.306 0 CA-C-O 121.917 0.865 . . . . 0.0 109.801 -179.271 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.558 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -132.88 151.35 34.18 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.621 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -58.88 116.81 4.02 Favored 'General case' 0 N--CA 1.514 2.766 0 CA-C-O 121.402 0.62 . . . . 0.0 111.904 -177.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . . . . . . . . . 31.0 m -123.41 152.05 41.99 Favored 'General case' 0 N--CA 1.51 2.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -77.27 -162.56 0.3 Allowed 'General case' 0 N--CA 1.504 2.273 0 CA-C-O 121.454 0.645 . . . . 0.0 111.252 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . 0.581 HD12 ' HA3' ' A' ' 412' ' ' GLY . 1.1 tt -81.42 -35.74 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.928 -0.483 . . . . 0.0 110.294 -179.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 53.86 55.98 7.73 Favored 'General case' 0 N--CA 1.51 2.562 0 CA-C-O 121.421 0.629 . . . . 0.0 110.146 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 N--CA 1.521 3.099 0 C-N-CA 123.879 0.872 . . . . 0.0 110.423 -179.537 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 409' ' ' CYS . . . . . . . . . . . . . 10.8 m . . . . . 0 CA--C 1.556 1.21 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 410' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -76.95 -171.07 1.04 Allowed 'Trans proline' 0 N--CA 1.499 1.829 0 C-N-CA 123.003 2.469 . . . . 0.0 112.765 -178.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 411' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -45.3 131.15 8.17 Favored 'General case' 0 N--CA 1.521 3.084 0 C-N-CA 122.806 0.442 . . . . 0.0 111.479 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 412' ' ' GLY . . . . . . . . . . . . . . . 94.35 -50.87 2.12 Favored Glycine 0 N--CA 1.504 3.208 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -177.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 413' ' ' TYR . . . . . . . . . . . . . 16.2 m-85 -78.49 87.34 4.48 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 414' ' ' ILE . . . . . 0.489 HD13 ' HB ' ' A' ' 422' ' ' THR . 0.0 OUTLIER -102.8 -170.67 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.522 3.153 0 O-C-N 121.53 -0.731 . . . . 0.0 110.984 -178.602 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 415' ' ' LEU . . . . . 0.523 ' HB3' ' HA ' ' A' ' 419' ' ' PHE . 3.9 mm? -100.55 123.1 44.3 Favored 'General case' 0 N--CA 1.5 2.038 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 416' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.94 -169.45 0.91 Allowed 'General case' 0 N--CA 1.517 2.883 0 O-C-N 121.923 -0.486 . . . . 0.0 111.097 -179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 417' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -51.98 -37.75 54.2 Favored 'General case' 0 N--CA 1.519 3.01 0 O-C-N 121.728 -0.608 . . . . 0.0 111.878 -179.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . -91.05 14.18 64.19 Favored Glycine 0 N--CA 1.508 3.484 0 CA-C-O 119.002 -0.888 . . . . 0.0 112.209 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 419' ' ' PHE . . . . . 0.523 ' HA ' ' HB3' ' A' ' 415' ' ' LEU . 10.8 t80 58.3 62.55 1.97 Allowed 'General case' 0 N--CA 1.506 2.33 0 CA-C-N 119.347 1.574 . . . . 0.0 110.08 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 420' ' ' ILE . . . . . 0.524 ' O ' HD12 ' A' ' 420' ' ' ILE . 2.1 pp -135.65 159.38 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.509 2.511 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.686 179.262 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 421' ' ' CYS . . . . . . . . . . . . . 3.3 t -65.7 102.84 0.79 Allowed 'General case' 0 N--CA 1.511 2.604 0 CA-C-O 121.464 0.65 . . . . 0.0 111.167 -178.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 422' ' ' THR . . . . . 0.489 ' HB ' HD13 ' A' ' 414' ' ' ILE . 7.8 m -84.53 168.41 15.44 Favored 'General case' 0 N--CA 1.514 2.75 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 423' ' ' ASP . . . . . 0.4 ' N ' HG22 ' A' ' 422' ' ' THR . 10.5 m-20 -64.81 -171.75 0.07 Allowed 'General case' 0 N--CA 1.505 2.32 0 O-C-N 121.585 -0.697 . . . . 0.0 110.589 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 424' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -81.98 -41.82 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.511 2.597 0 O-C-N 121.324 -0.86 . . . . 0.0 109.823 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 425' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 51.97 46.02 27.29 Favored 'General case' 0 N--CA 1.512 2.665 0 CA-C-O 121.525 0.678 . . . . 0.0 111.064 178.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 426' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.51 2.531 0 O-C-N 121.91 -0.494 . . . . 0.0 110.032 179.51 . . . . . . . . 1 1 . 1 stop_ save_